arsenic has been researched along with tretinoin in 503 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.20) | 18.7374 |
| 1990's | 29 (5.77) | 18.2507 |
| 2000's | 186 (36.98) | 29.6817 |
| 2010's | 246 (48.91) | 24.3611 |
| 2020's | 41 (8.15) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, ZY | 2 |
| Andre, C; Chelbi-Alix, MK; Chen, Z; de The, H; Degos, L; Dhumeaux, D; Guillemin, MC; Herve, L; Koken, MH; Quignon, F; Wang, ZY; Zhu, J | 1 |
| Cai, X; Chen, GQ; Chen, SJ; Chen, Z; de The, H; Han, ZG; He, KL; Jia, PM; Kitamura, K; Liu, MM; Ma, J; Miller, W; Naoe, T; Ni, JH; Niu, C; Paul, P; Shi, GY; Shi, XG; Tang, W; Wang, ZY; Waxman, S; Xiong, SM; Zhang, P; Zhang, TD; Zhu, J | 1 |
| Chen, Z; de Thé, H; Quignon, F | 1 |
| Look, AT | 1 |
| Avvisati, G; Davison, K; Fanelli, M; Ferrara, FF; Gambacorti-Passerini, C; Lamph, WW; Lo Coco, F; Miller, WH; Nervi, C; Pelicci, PG; Peschle, C; Riccioni, R; Rosenauer, A; Shao, W; Testa, U; Waxman, S | 1 |
| Benoit, G; Chelbi-Alix, MK; Chen, Z; de Thé, H; Giannì, M; Koken, MH; Lanotte, M | 1 |
| de Thé, H | 3 |
| Avvisati, G; Lo Coco, F; Mandelli, F; Nervi, C | 1 |
| Arima, T; Chyuman, Y; Hanada, S; Ishitsuka, K; Makino, T; Shimotakahara, S; Suzuki, S; Takeshita, T; Takeuchi, S; Uozumi, K; Utsunomiya, A | 1 |
| Ikeda, Y; Kinjo, K; Kizaki, M; Muto, A; Ueno, H | 1 |
| Harada, M; Kibata, M; Ohno, R; Omoto, E; Shudo, K; Takahashi, K; Takeuchi, M; Ueda, R; Yano, T | 1 |
| Buzyn, A; Daniel, MT; de Thé, H; Degos, L; Gianni, M; Koken, MH; Licht, J; Minard, P; Varet, B; Zelent, A | 1 |
| Bishop, JM; Daniel, MT; de Thé, H; Degos, L; Guillemin, MC; Janin, A; Kogan, SC; Lallemand-Breitenbach, V | 1 |
| Vincent, PC | 1 |
| Caen, J; Cai, X; Chen, GQ; Chen, SJ; Chen, Z; Guo, WM; Ju, B; Pan, L; Sun, GL; Wang, HL; Wang, ZY; Yao, YY; Zhao, WL; Zhu, J | 1 |
| Carmignani, A; Fazzi, R; Galimberti, S; Papineschi, F; Petrini, M; Testi, R | 1 |
| Agis, H; Edelhäuser, M; Fonatsch, C; Geissler, K; Lechner, K; Mitterbauer, G; Seewann, HL; Thalhammer, R; Valent, P; Weltermann, A | 1 |
| Haanen, C; Vermes, I | 1 |
| Donelli, A; Galimberti, S; Leonardi, G; Luppi, M; Marasca, R; Petrini, M; Torelli, G; Vaccari, P; Zucchini, P | 1 |
| Chen, SJ; Chen, Z; Hu, J; Shen, ZX; Sun, GL; Wang, ZY | 1 |
| Lehmann, S; Paul, C | 1 |
| Cai, X; Chen, GQ; Chen, SJ; Chen, Z; Huang, Y; Jia, PM; Shen, YL; Wang, ZY; Xiong, SM; Yu, Y; Zhang, JW; Zhou, L; Zhu, Q | 1 |
| Fukuchi, Y; Hata, J; Ikeda, Y; Ito, M; Kinjo, K; Kizaki, M; Muto, A; Nishihara, T; Ueyama, Y; Umezawa, A; Yamato, K | 1 |
| Kizaki, M | 1 |
| Hoshi, S; Kitamura, K; Kiyoi, H; Koike, M; Naoe, T; Saito, H | 1 |
| Hirosawa, S; Kamei, S; Koyama, T; Ohsawa, M; Shibakura, M | 1 |
| Chang, IY; Huang, MJ; Lin, CP; Lin, WY | 1 |
| Chang, IY; Huang, MJ; Lin, WY; Sheu, YT | 1 |
| Hayashi, T; Imanaka, T; Ishii, K; Komatsu, H; Nakamura, F; Ono, Y; Sawada, H; Tanaka, Y | 1 |
| Camacho, LH; Chanel, S; Ellison, R; Heller, G; Ho, R; Scheinberg, DA; Soignet, SL; Warrell, RP | 1 |
| Warrell, RP | 1 |
| He, LZ; Pandolfi, PP; Rego, EM; Wang, ZG; Warrell, RP | 1 |
| Hess, JL; Westervelt, P; Zhang, T | 1 |
| Bondesson, L; Garwicz, S; Jönsson, C; Ljungberg, J; Ora, I; Pâhlman, S; Pörn-Ares, I | 1 |
| Calleja, EM; Warrell, RP | 1 |
| Chen, GQ; Chen, Z; Jing, Y; Miller, WH; Wang, L; Waxman, S; Xia, L | 1 |
| Powell, BL | 1 |
| Cobcroft, R; Gill, D; Kennedy, GA; Marlton, P | 1 |
| Guo, W; Wang, H; Zhao, W | 2 |
| Cai, X; Jia, P; Shi, X | 1 |
| Guo, W; Qu, B; Shen, Z; Wang, H; Wang, X; Wang, Z; Wu, F; Zhao, W | 1 |
| Zelent, A | 1 |
| Altucci, L; Chomienne, C; Gronemeyer, H; Raffelsberger, W; Reitmair, A; Rossin, A | 1 |
| Al-Hashimi, S; Bazarbachi, A; Bazzi, R; Darwiche, N; de Thé, H; El-Sabban, M; Hermine, O; Nasr, R | 1 |
| Lane, AA; Ley, TJ; Pollock, JL; Walter, MJ; Westervelt, P | 1 |
| Au, WY; Chan, GC; Chim, CS; Ho, WK; Kwong, YL; Ooi, GC; Shek, TW | 1 |
| Pandolfi, PP | 1 |
| Huang, X | 2 |
| Castranova, V; Costa, M; Ding, M; Huang, C; Ju, G; Li, J; Shi, X; Vallyathan, V | 1 |
| Chelbi-Alix, MK; de Thé, H | 1 |
| Chen, GQ; Chen, SJ; Chen, Z; Wang, ZG; Wang, ZY; Zhang, TD | 1 |
| de Thé, H; Lallemand-Breitenbach, V; Zhu, J | 1 |
| Guo, W; Wang, H; Zhu, J | 1 |
| De Santis, S; Diverio, D; Lo Coco, F; Mandelli, F; Meloni, G; Petrucci, MT; Petti, MC; Pinazzi, MB; Romano, A; Tafuri, A | 1 |
| Chen, Z; Guo, W; Qu, B; Shen, Z; Wang, H; Wang, X; Wang, Z; Zhao, W | 1 |
| Hu, J; Li, X; Shen, Z; Sun, G; Sun, H; Wang, Z; Wu, W | 1 |
| Bi, K; Jiang, G; Tang, T | 1 |
| Cai, X; Chen, G; Chen, S; Huang, X; Jia, P; Shen, Y; Wang, L; Wang, Z; Yang, J; Yu, Y; Zhang, X; Zhou, L; Zhou, Y | 1 |
| Guo, W; Ju, B; Wang, H; Wang, X; Zhao, W; Zhu, J | 1 |
| Cai, X; Huang, X; Zhou, Y | 1 |
| Shen, Z; Wang, H; Wang, X; Wu, F; Zhao, W | 1 |
| Qiao, Z; Yang, L; Zhang, X | 1 |
| Chen, G; Pan, L; Zhou, L | 1 |
| Feusner, JH; Nabhan, C; Rowe, JM; Tallman, MS | 1 |
| Douer, D | 1 |
| Akiyama, H; Fukuhara, O; Hiruma, K; Maeda, Y; Mikoshiba, M; Ohashi, K; Okuyama, Y; Sakamaki, H; Takei, N; Takeshita, A | 1 |
| Chu, H; Guo, W; Pan, L; Qu, B; Wang, H; Wang, X; Zhao, W; Zhu, J | 1 |
| Chen, F; Li, Y; Xu, G; Zhang, M | 1 |
| Chen, Z; Wang, ZY | 2 |
| Au, WY; Chim, CS; Kwong, YL; Liang, R; Lie, AK | 1 |
| Fujisawa, S; Fujita, Y; Matsui, H; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Satoh, H; Shigeno, K; Shinjo, K; Takeshita, A; Terada, H; Yoshida, H | 1 |
| Bloomfield, CD; Slack, JL; Tallman, MS; Tricot, G; Waxman, S | 1 |
| Tallman, MS | 6 |
| DiPersio, JF; Ley, TJ; Ma, MK; Oldfather, KM; Pollock, JL; Walter, MJ; Westervelt, P; Williams, A | 1 |
| Jing, Y; Waxman, S; Xia, L | 1 |
| Lopez-Berestein, G; Ozpolat, B | 1 |
| Nabhan, C; Tallman, MS | 1 |
| Guo, P; Hu, Y; Qiao, Z; Shen, G; Song, S; Wang, J; Yang, L; Zhang, X; Zhou, H | 1 |
| Wiśniewska, E; Wysocki, R | 1 |
| Daniel, MT; De Thé, H; Degos, L; Dombret, H; Gourmel, B; Guillemin, MC; Janin, A; Kogan, S; Lallemand-Breitenbach, V; Lanotte, M; Raffoux, E; Soilihi, H; Vitoux, D; Zhu, J | 1 |
| Au, WY; Chim, CS; Chung, LP; Kwong, YL; Ma, SK | 1 |
| Li, B; Lou, FD; Wang, YZ; Yao, SQ; Yu, L; Zhu, HL | 1 |
| Cai, X; Chen, SJ; Chen, Z; Jia, PM; Tong, JH; Wang, ZY; Yu, Y; Zhu, Q | 1 |
| Cao, Q; Chen, SJ; Chen, X; Chen, Z; Liu, YF; Shen, ZX; Wang, AH; Wang, ZY; Zhu, YM | 1 |
| Li, DP; Li, HQ; Li, R; Qi, JY; Qian, LS; Wan, CC; Wang, ZQ; Zhao, YZ; Zhou, CL | 1 |
| Baccarani, M; Malagola, M; Martinelli, G; Piccaluga, PP; Rossi, M; Visani, G | 1 |
| DiPersio, J; Douer, D; Giralt, S; Hu, W; Lill, M | 1 |
| Chen, SY; Li, XM; Liu, SX | 1 |
| Buzyn, A; Cassinat, B; Chomienne, C; Cimerman, P; Daniel, MT; de Thé, H; Degos, L; Delarue, R; Dombret, H; Fermand, JP; Hermine, O; Lebbé, G; Poupon, J; Raffoux, E; Réa, D; Rousselot, P; Taksin, AL; Tibi, A | 1 |
| Au, WY; Chan, GC; Kou, M; Kumana, CR; Kwong, YL; Lam, CW; Mak, R | 1 |
| Jing, Y; Lu, M; Waxman, S; Xia, L | 1 |
| Stull, DM | 1 |
| Degos, L | 2 |
| Grigg, A; Kimber, R; Szer, J | 1 |
| Bao, L; Jiang, H; Liu, YR; Lu, DP; Qin, YZ; Wang, FR; Wang, JZ | 1 |
| Udvardy, M | 1 |
| Benoit, G; Bobé, P; Canova, A; Chelbi-alix, MK; Pine, R | 1 |
| Takeshita, A | 1 |
| Liu, SX; Zhao, XA | 1 |
| Chen, SJ; Chen, Y; Chen, Z; De Thé, H; Fang, J; Gu, BW; Li, JM; Liu, YF; Shen, Y; Shen, ZX; Shi, JY; Shi, ZZ; Tang, W; Wang, ZY; Waxman, S; Wu, W; Yan, H; Zheng, PZ; Zhu, YM | 1 |
| Bradley, D | 1 |
| Hong, WD; Li, J; Li, QH; Luo, SK; Peng, AH; Tan, EX; Tong, XZ; Zhang, GC; Zheng, D | 1 |
| Cannizzaro, L; Ding, W; Gallagher, RE; Guidez, F; Kim, SH; Paietta, E; Ramesh, KH; Sun, Y; Warrell, RP; Zelent, A; Zhou, DC | 1 |
| Jing, Y | 1 |
| Dryden, MJ; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; Pierce, S; Ratnam, S; Tsimberidou, AM; Whitman, GJ | 1 |
| Feusner, J; Gregory, J; Ravindranath, Y | 1 |
| Cai, L; Cui, J; Gao, S; Jiang, Z; Li, W; Liu, Z; Song, Y; Wang, G; Yang, Y; Yao, C; Yuan, CJ | 1 |
| Li, J; Shen, T; Wang, X; Xu, CM; Yang, Y; Zhang, ZN; Zuo, L | 1 |
| Kwong, YL | 2 |
| Civallero, M; Cosenza, M; Marcheselli, R; Pozzi, S; Sacchi, S | 1 |
| Chen, G; Chen, L; Chen, S; Li, X; Ni, J; Shen, Z; Tang, W; Wang, Z; Xiong, S; Zhong, H; Zhu, J | 1 |
| Du, J; Liu, BR; Qian, XP; Wang, LF; Yin, HT; Zou, ZY | 1 |
| Benecke, A; Cayre, YE; Denis, FM; Di Gioia, Y; Lutz, PG; Touw, IP | 1 |
| Bastien, J; Bauer, A; Bruck, N; Gianni, M; Rochette-Egly, C; Tarrade, A | 1 |
| Chen, SJ; Chen, Z; Wang, ZY; Zhao, WL; Zhou, GB | 1 |
| Ikeda, T; Kimura, F; Kufe, D; Motoyoshi, K; Nakata, Y; Ogura, K; Sato, K; Sporn, M | 1 |
| Beal, N; Diehl, LF; Huff, CA; Jones, RJ; Matsui, W; Smith, BD; Vala, M | 1 |
| Chen, SJ; Zhao, WW | 1 |
| Auffray, C; Chen, SJ; Chen, YL; Chen, Z; Du, YZ; Eveno, E; Fan, HY; Huang, QH; Imbeaud, S; Jin, G; Shen, SH; Wang, KK; Waxman, S; Xiao, DK; Zhang, J; Zhang, QH; Zhang, QY; Zhao, CJ; Zheng, PZ | 1 |
| Horii, T; Maekawa, M; Matsui, H; Naito, K; Naoe, T; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Shirai, N; Takeshita, A | 1 |
| Cui, JW; Gao, SJ; Jiang, ZY; Li, W; Liu, ZL; Song, YQ; Wang, GJ; Yang, Y; Yao, C; Yuan, CJ | 1 |
| Aradi, J; Dudognon, C; Hillion, J; Lanotte, M; Pendino, F; Ségal-Bendirdjian, E; Tarkanyi, I | 1 |
| Kobayashi, M; Maekawa, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A | 1 |
| Chen, SJ; Chen, Z; Zhou, GB | 1 |
| Hu, Y; Qiao, Z; Song, S; Yang, L; Zhang, X; Zhou, H | 1 |
| Büchner, T; Hehlmann, R; Lengfelder, E; Saussele, S; Weisser, A | 1 |
| Li, BX; Lin, DH; Lin, LM; Xiao, JB; Yang, BF | 1 |
| Tamm, I | 1 |
| Chen, GQ; Huang, Y; Jiang, Y; Peng, ZG; Wu, YL; Yan, H; Yu, Y; Zhao, Q; Zhu, YS | 1 |
| Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Jones, D; Kantarjian, H; Verstovsek, S | 1 |
| Frankfurt, O; Tallman, MS | 1 |
| Benedusi, M; Bertagnolo, V; Bovolenta, M; Brugnoli, F; Capitani, S; Miscia, S | 1 |
| Ades, L; Bordessoule, D; Castaigne, S; Chevret, S; de Botton, S; Degos, L; Dombret, H; Fegueux, N; Fenaux, P; Guerci, A; Kelaidi, C; Link, H; Meyer-Monard, S; Raffoux, E; Rayon, C; Rigal-Huguet, F; Sanz, M; Stoppa, A; Thomas, X; Vekhoff, A | 1 |
| Jing, Y; Waxman, S; Wurmbach, E; Xia, L | 1 |
| Fukai, Y; Hirata, M; Ichikawa, N; Kaise, T; Kinoshita, K; Kobayashi, H; Ohta, S; Saitoh, H; Sakurai, T; Ueno, M | 1 |
| Caillot, D; Fenaux, P; Huguet, F; Pigneux, A; Raffoux, E; Thomas, X | 1 |
| Kai, T; Kimura, H; Maruyama, Y; Ogawa, K; Sato, H; Shiga, Y | 1 |
| Deng, SH; Han, MZ; Li, QC; Li, X; Li, Y; Li, YT; Li, ZJ; Qiu, LG; Wan, CC; Yang, RC; Zhao, YZ | 1 |
| Duan, LN; Guo, ZK; Ji, SQ; Wang, HX | 1 |
| Kwong, YL; Leung, J; Pang, A; Tse, EW; Yuen, WH | 1 |
| Ohnishi, K | 2 |
| Chang-chun, W; Jian-xiang, W; Lu-gui, Q; Ming-zhe, H; Qiao-chuan, L; Ren-chi, Y; Wan-jun, S; Xin, L; Yan, L; Yao-zhong, Z; Yun-tao, L; Zeng-jun, L | 1 |
| Ewer, MS; Jones, RL | 1 |
| Estey, E; Kantarjian, H; Keating, MJ; Tsimberidou, AM | 1 |
| Avvisati, G; Breccia, M; Buffolino, S; Cimino, G; De Angelis, G; Lo-Coco, F; Mariella, M; Martini, V; Minotti, C | 1 |
| Jing, Y; Waxman, S | 1 |
| Bi, KH; Jiang, GS | 1 |
| Akar, U; Berestein, GL; Colburn, N; Danilenko, M; Kornblau, S; Ozpolat, B; Steiner, M; Tirado-Gomez, M; Zorrilla-Calancha, I | 1 |
| Chen, SJ; Chen, Z; Wang, ZY; Zhang, J; Zhou, GB | 1 |
| Aribi, A; Cortes, JE; Estey, EH; Faderl, SH; Garcia-Manero, G; Kantarjian, HM; Koller, CA; Kornblau, SM; Laddie, NM; Thomas, DA | 1 |
| Ammatuna, E; Lo Coco, F; Sanz, MA | 1 |
| Beissert, T; Bug, G; Henschler, R; Hoelzer, D; Puccetti, E; Rüster, B; Ruthardt, M; Seshire, A; Zheng, X | 1 |
| Besançon, F; Mathieu, J | 1 |
| de The, H; Nasr, R; Vitoux, D | 1 |
| Guo, T; Hong, M; Hu, Y; Shen, GX; Song, SJ; Wei, WN; Xia, LH; Zhang, XH | 1 |
| Berridge, MV; Herst, PM; Hesketh, EL; Ritchie, DS | 1 |
| Berman, JN; Look, AT | 1 |
| Farhat, M; Venugopal, P | 1 |
| Ma, J | 1 |
| Du, JW; Fang, BJ; Gao, QL; Hu, JY; Jiang, DX; Li, YF; Lin, QD; Liu, YY; Song, YP; Wang, P; Wei, XD; Yue, H; Zhang, LN; Zhang, YL; Zhu, XH | 1 |
| Albihn, A; Henriksson, M; Jiang, G; Tang, T; Tian, Z | 1 |
| Campbell, LJ; Catalano, A; Dawson, MA; Iland, H; Opat, S; Schwarer, A; Somana, K | 1 |
| Chen, GQ; Wang, LS; Wu, YL; Yu, Y | 1 |
| Chen, SJ; Chen, Z; Li, G; Zhou, GB | 1 |
| Chen, SY; Dong, Y; Guo, WJ; Ma, LH; Wang, ZY | 1 |
| Dai, CW; Pei, MF; Shen, JK; Xu, YX; Zhang, GS; Zheng, WL | 1 |
| Cunha De Santis, G; Cunha, FQ; Faccioli, LH; Falcão, RP; Garcia, AB; Lima, AS; Moreno, SE; Rego, EM; Secco, D; Sousa, RB; Tamarozzi, MB | 1 |
| Li, D; Wei, F; Zhang, W; Zhang, X | 1 |
| Estey, E; Kopp, L; Quezada, G; Wells, RJ | 1 |
| Bazarbachi, A; de Thé, H; Habib, A; Hamade, E; Mahfouz, R; Nasrallah, MS | 1 |
| Isobe, Y; Oshimi, K; Sasaki, M; Sugimoto, K | 1 |
| Chen, X; Chen, Y; Zhang, L; Zhao, H; Zhu, X; Zou, Y | 1 |
| Acevedo-Alvarez, M; Akar, U; Lopez-Berestein, G; Ozpolat, B; Vivas-Mejia, P; Zorrilla-Calancha, I | 1 |
| Ammatuna, E; Lo-Coco, F; Montesinos, P; Sanz, MA | 1 |
| Grzanka, A; Izdebska, M; Litwiniec, A; Szczepański, MA | 1 |
| Arar, K; Barbry, P; Bouttier, M; Cassinat, B; Chomienne, C; Friederich, E; Lecellier, CH; Mari, B; Maurin, T; Portales-Casamar, E; Saumet, A; Vallar, L; Vetter, G; Wasserman, WW | 1 |
| Dalley, CD; Ezaydi, Y; Goepel, JR; Kirkbride, P; Krishna, R; Smith, DJ; Snowden, JA; Sorour, Y | 1 |
| Horikoshi, A; Iriyama, N; Kaise, T; Miyashita, SI; Shikino, O; Toyoda, H; Yoshino, Y; Yuan, B | 1 |
| Abreu e Lima, RS; Falcão, RP; Freitas, RA; Garcia, AB; Gimenes Teixeira, HL; Jordão, AA; Lima, AS; Lucena-Araujo, AR; Rego, EM; Scheucher, PS; Silva dos Santos, GA; Vannucchi, H | 1 |
| Cheng, YF; Liu, CF; Liu, GL; Lu, AD; Wang, B; Zhang, LP | 1 |
| Altman, JK; Tallman, MS | 2 |
| Haferlach, T | 1 |
| Blamble, D; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Ferrajoli, A; Fiorentino, J; Garcia-Manero, G; Jones, D; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Verstovsek, S; Wierda, W | 1 |
| Fang, H; Wang, K; Zhang, J | 1 |
| Bao, L; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lin, W; Liu, YR; Lu, J; Lu, XJ; Zhang, Y | 1 |
| Brossart, P; Fröhlich, E; Wahl, R | 1 |
| Kogan, SC | 1 |
| Chen, B; Chen, QS; Chen, SJ; Chen, Z; Hu, J; Li, JM; Liu, YF; Shen, ZX; Sun, HP; Tang, W; Wang, ZY; Waxman, S; Wu, CF; Wu, W; Xu, F; Zelent, A; Zhao, WL; Zhou, GB; Zhu, YM | 1 |
| Licht, JD | 1 |
| Cao, YX; Dai, CW; Li, RJ; Pei, MF; Peng, HL; Shen, JK; Xu, YX; Yang, JJ; Yi, Y; Zhang, GS; Zheng, WL; Zhong, HY | 1 |
| Tang, DZ; Tao, S; Zhou, K | 1 |
| Petrie, K; Waxman, S; Zelent, A | 1 |
| Lu, DP; Zhang, M; Zhao, XH; Zhu, HJ | 1 |
| Angell, R; Aslett, H; Batson, E; Burnett, AK; Clark, RE; Diverio, D; Flora, R; Grimwade, D; Hills, RK; Jones, K; Jovanovic, JV; Lo-Coco, F; Nugent, EA; Patel, Y; Rennie, K; Solomon, E; Wheatley, K | 1 |
| Duggan, J; Siderov, J | 1 |
| Ravandi, F | 3 |
| Dai, L; Liu, YH; Ruan, CG; Shen, WH; Wang, ZY; Zhang, W | 1 |
| Kurokawa, M; Nagai, S; Takahashi, T | 2 |
| Balasubramanian, P; Chandy, M; Chendamarai, E; George, B; Lakshmi, KM; Mathews, V; Srivastava, A; Thirugnanam, R; Viswabandya, A | 1 |
| de Witte, TJ; Jansen, JH; Linssen, PC; Luesink, M; Muus, P; Pennings, JL; Pfundt, R; van der Reijden, BA; Wissink, WM | 1 |
| Feusner, J; Gregory, J | 1 |
| Leu, L; Mohassel, L | 1 |
| Chen, JP; Liu, JP; Xia, Y; Xu, SN | 1 |
| Li, L; Zhang, ZH; Zhao, WD | 1 |
| Duan, MH; Han, B; Jiao, L; Shen, T; Wang, SJ; Xu, Y; Zhang, W; Zhao, YQ; Zhou, DB; Zhu, TN; Zhuang, JL; Zou, N | 1 |
| Hatta, Y; Hirabayashi, Y; Ishizuka, H; Kobayashi, Y; Takei, K; Takeuchi, J; Tanaka, T | 1 |
| Fukushima, N; Hisatomi, T; Ide, M; Itamura, H; Kimura, S; Sueoka, E; Tanaka, M; Tomimasu, R; Urata, C; Yokoo, M | 1 |
| Arceci, R; Dauses, T; Devetten, M; Gallagher, RE; Gojo, I; Gore, SD; Jamieson, K; Morris, L; Owoeye, I; Redner, RL; Schachter-Tokarz, E; Sekeres, MA | 1 |
| Cao, F; Gilbert, GE; Heegaard, CW; Hou, J; Rasmussen, JT; Shi, J; Zhang, Y; Zhou, J | 1 |
| Altman, JK; Dolniak, B; Glaser, H; Goussetis, DJ; Kroczynska, B; McNeer, JL; Platanias, LC; Sassano, A | 1 |
| Ferrara, F | 1 |
| Grimwade, D; Guidez, F; Mistry, AR; Solomon, E | 1 |
| Arora, N; Das, R; Malhotra, P; Nath, A; Patel, FD; Varma, N; Varma, S | 1 |
| Chen, W; He, P; Qi, J; Wang, H; Wang, X; Zhang, M | 1 |
| de Thé, H; Nasr, R | 1 |
| Bian, S; Hao, L; Li, J; Wang, H; Wang, X; Wu, Q | 1 |
| Blinder, R; Chang, P; Galinsky, I; Ho, VT; Housman, E; Kesari, S; Lane, SW; Mullally, A; Stone, RM | 1 |
| Bjørås, M; Bøe, SO; Isakson, P; Simonsen, A | 1 |
| Bloom, SE; Bunaciu, RP; Nayak, S; Shen, M; Varner, JD; Yen, A | 1 |
| Appelbaum, FR; Couban, S; Coutre, S; Feusner, JH; Gallagher, RE; Gregory, J; Larson, RA; Moser, B; Powell, BL; Rowe, JM; Stock, W; Stone, RM; Tallman, MS; Willman, CL | 1 |
| Bøe, SO; Simonsen, A | 1 |
| Cortes, J; Dayyani, F; Faderl, S; Garcia-Manero, G; Jones, D; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F | 1 |
| Chung, JG; Huang, WW; Kuo, SC; Lai, IC; Lai, TY; Lin, CC; Lin, JJ; Wen, YF; Yang, JS | 1 |
| Fu, CC; Jin, ZM; Liang, JY; Liu, YJ; Ma, X; Qiu, HY; Tang, XW; Wu, DP | 1 |
| Douer, D; Gore, S; Powell, BL; Ranganathan, A; Ravandi, F; Rowe, J; Sanz, MA; Tallman, M | 1 |
| Hasan, SK; Lo-Coco, F | 2 |
| Dai, L; Jiang, M; Liu, Y; Ruan, C; Wang, Z; Wu, D; Zhang, W | 1 |
| Lo-Coco, F; Sanz, MA | 1 |
| Manji, GA; Tallman, MS | 1 |
| Gong, YP; Luo, S; Yang, L; Yang, YM | 1 |
| Chen, X; Chen, Y; Zhang, L; Zhu, X; Zou, Y | 1 |
| Rogers, JE; Yang, D | 1 |
| Gore, SD; Prebet, T | 1 |
| Chen, Z; Jin, J; Li, K; Mei, C; Tong, H; Wang, H | 1 |
| Anderson, LD; Collins, RH; Kirk, A; Levitt, D; Naina, HV; Scaglioni, PP; Vusirikala, M | 1 |
| He, PC; Qi, J; Zhang, M | 1 |
| Alimoghaddam, K; Ghaffari, H; Ghavamzadeh, A; Hosseini, R; Iravani, M; Jahani, M; Jalili, M; Mousavi, A; Rostami, S | 1 |
| Geng, XX; Ma, R; Quan, LN; Tang, LP | 1 |
| Estey, EH; Hutchinson, F | 1 |
| Breccia, M; Cicconi, L; Giannì, L; Latagliata, R; Lo-Coco, F; Minotti, C | 1 |
| Hu, J | 1 |
| Chen, HZ; Chen, XY; Qi, H; Rong, ZX; Wang, BS; Wang, H | 1 |
| Akashi, K; Harada, M; Kamimura, T; Miyamoto, T | 1 |
| Shinagawa, K | 1 |
| Abreu e Lima, RS; Curti, C; de Thé, H; dos Santos, GA; Falcão, RP; Gimenes-Teixeira, HL; Lima, AS; Lucena-Araujo, AR; Nasr, R; Pandolfi, PP; Pestana, CR; Rego, EM; Rodrigues, FP; Santana-Lemos, BA; Scheucher, PS; Thomé, CH; Uyemura, SA | 1 |
| Park, JH; Tallman, MS | 1 |
| Chatterjee, A; Chatterji, U | 2 |
| Au, WY; Kumana, CR; Kwong, YL; Lau, JS; Lee, HK; Lin, SY; Liu, H; Yeung, DY | 1 |
| Gurung, A; Huang, BT; Li, BS; Xiao, Z; Zeng, QC; Zhao, WH | 1 |
| Chen, S; Fang, Y; Li, X; Liu, S; Ma, L | 1 |
| Mi, J | 1 |
| Brenneman, MA; Chen, JD; Denissova, NG; Hakhverdyan, Z; Nasello, C; Yeung, PL | 1 |
| Inoue, A; Kawakami, C; Takitani, K; Tamai, H | 1 |
| Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ | 1 |
| Chen, Y; Li, Z; Lu, Q | 1 |
| Chen, P; Chen, YZ; Huang, HF; Lin, ZX; Lu, R; Wu, Y | 1 |
| Cao, Z; Li, Q; Ruan, M; Wang, J; Zhang, L; Zhu, X; Zou, Y | 1 |
| Chen, SJ; Chen, Z; Li, JM; Mi, JQ; Shen, ZX | 1 |
| Benoilid, A; Broly, F; Echaniz-Laguna, A; Fornecker, LM; Goullé, JP; Lannes, B; Mousson de Camaret, B; Vinzio, S | 1 |
| Breccia, M; Lo-Coco, F | 1 |
| Huang, H; Liu, H; Qin, Y; Teng, R; Xu, M; Xu, R; Yang, L; You, X | 1 |
| Guo, WW; Liu, WJ | 1 |
| Choudhry, A; DeLoughery, TG | 1 |
| Arcese, W; Aversa, F; Bacigalupo, A; Breccia, M; Camboni, A; Cupelli, L; Di Veroli, A; Iori, AP; Lo-Coco, F; Papayannidis, C; Ramadan, SM | 1 |
| Chen, Y; Cortes, J; Kantarjian, H; Ravandi, F; Wang, H | 1 |
| Chen, SJ; Zhou, GB | 1 |
| Bashford, J; Bradstock, K; Browett, P; Catalano, A; Collins, M; Di Iulio, J; Filshie, R; Firkin, F; Grigg, A; Hertzberg, M; Hugman, A; Iland, HJ; Moore, J; Reynolds, J; Seldon, M; Seymour, JF; Supple, SG; Szer, J; Taper, J; Taylor, K; Tiley, C | 1 |
| de Thé, H; Lallemand-Breitenbach, V; Le Bras, M | 1 |
| Stein, EM; Tallman, MS | 2 |
| Chang, MC; Chang, YF; Chen, CG; Chiang, YH; Hsieh, RK; Lim, KH; Lin, HC; Lin, J | 1 |
| Park, JH | 1 |
| Aizawa, S; Hatta, Y; Horikoshi, A; Iriyama, N; Takeuchi, J; Toyoda, H; Yoshino, Y; Yuan, B | 1 |
| Chen, YZ; Li, XF; Liao, XY; Wu, Y; Yang, JH | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y | 2 |
| Aul, C; Berdel, WE; Braess, J; Büchner, T; Erben, P; Haferlach, C; Haferlach, T; Hanfstein, B; Hehlmann, R; Heinecke, A; Hiddemann, W; Hofmann, WK; Horst, HA; Kreuzer, KA; Krug, U; Lengfelder, E; Müller-Tidow, C; Sauerland, C; Schneider, S; Schnittger, S; Schultheis, B; Serve, H; Spiekermann, K; Wörmann, B | 1 |
| Chen, P; Chen, YZ; Huang, HF; Lu, R; Wu, Y | 1 |
| Cao, J; Chen, D; Chen, L; Du, X; Fan, Z; Li, S; Lin, L; Liu, X; Ma, J; Pei, R; Sha, K; Tang, S; Wu, J; Ye, P; Zhang, B; Zhang, P | 1 |
| Chen, MH; Liu, M; Liu, TB; Xle, JM; Yang, AQ; Yang, P | 1 |
| Attarbaschi, A; Boztug, H; Chen, HY; Cooper, BW; Dworzak, MN; König, M; Strehl, S; Suzukawa, K; Zhang, SJ | 1 |
| Chen, H; Liu, J; Liu, L; Liu, M; Shi, B; Ye, L; Yu, L; Zhang, Y | 1 |
| Iland, HJ; Seymour, JF | 1 |
| Ablain, J; Anthony, E; de Thé, H; Fonsart, J; Leiva, M; Peres, L | 1 |
| Cao, JJ; Chen, D; Chen, LG; Du, XH; Fan, Z; Li, SY; Lin, L; Liu, XH; Ma, JX; Pei, RZ; Sha, KY; Shi, XW; Tang, SH; Wu, JY; Ye, PP; Zhang, BB; Zhang, PS; Zhuang, XX | 1 |
| Belin, E; Chesnut, G; Taylor, S | 1 |
| Kiyoi, H; Naoe, T; Tomita, A | 1 |
| Hofmann, WK; Lengfelder, E; Nolte, F | 2 |
| Fan, H; Li, S; Lin, J; Lu, X; Zhu, H | 1 |
| Jia, XH; Liu, JQ; Wang, KK; Wang, P; Xi, WD; Yang, XW; Zhang, H | 1 |
| He, Y; Huang, S; Mao, C; Qin, X; Sun, X; Zhu, L | 1 |
| Chen, M; Liu, T; Niu, T; Wang, L; Xie, LP; Zeng, K; Zou, XL | 1 |
| Asou, N; Fujita, H; Hyo, R; Inaguma, Y; Ishigatsubo, Y; Iwanaga, M; Izumi, T; Kiyoi, H; Matsuda, M; Miyawaki, S; Miyazaki, Y; Nakaseko, C; Naoe, T; Nomura, S; Ohnishi, K; Ohtake, S; Okada, M; Shinagawa, K; Takeshita, A; Yamauchi, T | 1 |
| Amadori, S; Avvisati, G; Brandts, CH; Breccia, M; Carella, AM; Cazzola, M; Cerqui, E; Cicconi, L; Ciceri, F; Di Bona, E; Divona, M; Döhner, H; Döhner, K; Ehninger, G; Fabbiano, F; Fazi, P; Ferrara, F; Fiedler, W; Finizio, O; Fioritoni, G; Ganser, A; Hänel, M; Hertenstein, B; Iacobelli, S; Kropp, MG; La Nasa, G; Levis, A; Link, H; Lo-Coco, F; Lübbert, M; Luppi, M; Mandelli, F; Melillo, L; Morra, E; Orlando, SM; Platzbecker, U; Rambaldi, A; Salih, HR; Sauer, M; Schlenk, RF; Schmitz, N; Sica, S; Specchia, G; Thiede, C; Venditti, A; Vignetti, M; von Lilienfeld-Toal, M; Wattad, M | 1 |
| Chen, SJ; Chen, Z | 2 |
| Chen, X; Shao, J; Yan, J | 1 |
| Kuo, TC; Tian, TF; Tseng, YJ | 1 |
| de Thé, H; Lallemand-Breitenbach, V | 1 |
| Mehta, SV; Shukla, SN; Vora, HH | 1 |
| Fung, TK; So, CW | 1 |
| Chen, Z; Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Suo, S; Tong, H; Tong, Y; Wang, Y; Ye, X | 1 |
| Iacoboni, G; Montesinos, P; Sanz, MA | 2 |
| Huang, XJ; Jiang, B; Lai, YY; Liu, YR; Qin, YZ; Shi, HX; Zhu, HH | 1 |
| Cheng, Y; Liu, G; Lu, A; Wang, B; Wu, J; Zhang, L | 1 |
| Mayor, S | 1 |
| Chen, L; Hu, X; Wang, J; Xu, X | 1 |
| Hasan, SK; Lo-Coco, F; Montesinos, P; Sanz, MA | 1 |
| Lo-Coco, F; Orlando, SM; Platzbecker, U | 1 |
| Miura, Y; Suyama, K; Takano, T | 1 |
| Chen, SJ; Huang, XJ; Jiang, H; Jin, J; Li, JY; Ma, J; Wang, JX; Wu, DP; Zhu, HH | 1 |
| Douer, D; Ganzel, C; Tallman, MS | 1 |
| Dos Santos, GA; Kats, L; Pandolfi, PP | 1 |
| Macheta, A; Podhorecka, M | 1 |
| Albert, L; Jhanwar-Uniyal, M; Karsy, M; Murali, R | 1 |
| Ablain, J; de Reynies, A; de Thé, H; Minucci, S; Rice, K; Soilihi, H | 1 |
| Cheng, X; He, P; Liu, F; Liu, Y; Shi, L; Wang, Y; Zhang, M; Zhao, J; Zhou, N; Zhu, H | 1 |
| Breccia, M; Cicconi, L; Lo-Coco, F | 2 |
| Ansari, M; Bourquin, JP; Gumy-Pause, F; Huezo-Diaz, P; Judas, C; Mattiello, V; Rock, N | 1 |
| Altman, JK; Appelbaum, FR; Attar, EC; Coutre, SE; Gore, SD; Kopecky, KJ; Larson, RA; Levitan, D; Maher, T; Othus, M; Paietta, E; Powell, B; Stock, W; Tallman, MS; Wetzler, M; Willman, CL | 1 |
| Chen, L; Gao, L; Hu, X; Lü, S; Song, X; Wang, J; Yang, J; Zhang, W | 1 |
| Montesinos, P; Sanz, MA | 1 |
| de Thé, H; Rice, KL | 1 |
| Altman, JK; Cull, EH | 1 |
| Cicconi, L; Lo-Coco, F | 4 |
| Chen, P; Chen, YZ; Huang, HF; Wu, JY | 1 |
| Guan, X; Li, C; Li, M; Shu, X; Sun, Y | 1 |
| Cull, EH; Kwaan, HC | 1 |
| Garnier, N; Miller, WH; Nichol, JN | 1 |
| Iland, HJ; Seymour, JF; Wei, A | 1 |
| Grimwade, D; Hills, RK; Jovanovic, JV | 1 |
| Douer, D; Ganzel, C | 1 |
| Feusner, JH; Gregory, J; Kutny, MA | 1 |
| Komatsu, N | 1 |
| Chen, S; Chen, Z; Hu, J; Li, J; Mi, J; Wang, Z; Zhu, H | 1 |
| Cheong, HJ; Jung, YS; Kim, KH; Kim, SJ; Lee, N; Park, HS; Won, JH | 1 |
| Breccia, M; Efficace, F; Foà, R; Latagliata, R; Lo Coco, F; Minotti, C; Molica, M | 1 |
| Buc Calderon, P; Felipe, KB; Glorieux, C; Kviecinski, MR; Sandoval, JM; Sid, B; Stockis, J; Valenzuela, M; Verrax, J | 1 |
| Liu, F; Wang, W; Wei, J; Ye, C | 1 |
| Cortes, J; Daver, N; Eghtedar, A; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Rodriguez, I | 1 |
| Fang, ZG; He, Y; Hu, Y; Huang, RW; Li, XD; Lin, DJ; Liu, JJ; Liu, Q; Long, ZJ; Wang, DN; Xiao, RZ; Yan, JS | 1 |
| Chen, RL; Huang, BT; Li, BS; Zeng, QC; Zhao, WH | 1 |
| He, Y; Hu, Y; Huang, R; Li, X; Wang, D; Wang, W; Xiao, R; Zhang, E | 1 |
| Bally, C; de Thé, H; Lehmann-Che, J | 1 |
| Amadori, S; Avvisati, G; Breccia, M; Cerqui, E; Cottone, F; Di Bona, E; Efficace, F; Ferrara, F; Finizio, O; Fioritoni, G; Kropp, MG; Levis, A; Lo-Coco, F; Mandelli, F; Platzbecker, U; Schlenk, RF; Sica, S; Specchia, G; Vignetti, M | 1 |
| Arteaga, MF; Fung, TK; Mikesch, JH; So, CW | 1 |
| Ablain, J; de Reynies, A; de Thé, H; Halftermeyer, J; Le Bras, M; Metzger, D; Peres, L; Vitaliano-Prunier, A | 1 |
| Gore, SD; Zeidan, AM | 1 |
| Fujita, H | 1 |
| Anderlini, P; Borthakur, G; Brandt, M; Cortes, J; Daver, N; Dinardo, C; Ferrajoli, A; Garcia-Manero, G; Hosing, C; Kadia, T; Kantarjian, H; Marcucci, G; O'Brien, S; Pemmaraju, N; Pierce, S; Popat, U; Ravandi, F; Verstovsek, S | 1 |
| Nitto, T; Sawaki, K | 1 |
| Barakat, S; Couban, S; Lachaine, J; Mathurin, K | 1 |
| Arai, M; Hirano, T; Onda, K; Sakai, C; Sugiyama, K; Tanaka, S | 1 |
| Huang, XJ; Zhu, HH | 2 |
| Fischer, T; Koehler, M | 1 |
| Cottone, F; Efficace, F; Lo-Coco, F | 1 |
| Brunetti, L; Di Raimondo, F; Falini, B; Gionfriddo, I; Martelli, MP; Mezzasoma, F; Milano, F; Mulas, F; Pacini, R; Pettirossi, V; Pierangeli, S; Rossi, R; Sportoletti, P; Tabarrini, A; Tiacci, E; Vetro, C | 1 |
| Ades, L; Bazarbachi, A; Berthier, C; Darwiche, N; Dassouki, Z; de Thé, H; Dombret, H; El Hajj, H; Fenaux, P; Hleihel, R; Legrand, O; Mohty, M; Raffoux, E; Sahin, U; Salameh, A; Tawil, N; Zibara, K | 1 |
| Abraham, A; Aiyaz, M; Alex, AA; Balasubramanian, P; Chandy, M; Chendamarai, E; Chomienne, C; Ganesan, S; George, B; Janet, NB; Kamath, V; Lakshmi, KM; Mathews, V; Mugasimangalam, R; Mullapudi, N; Nair, SC; Nellickal, AJ; Padua, RA; Srivastava, A; Srivastava, V; Viswabandya, A | 1 |
| Inomata, T; Sunami, K | 1 |
| Guo, QL; Jiang, NJ; Liu, WJ; Xu, Q | 1 |
| Coombs, CC; Tallman, MS; Tavakkoli, M | 1 |
| Ma, H; Yang, J | 1 |
| Bernardi, R; Coltella, N; Ponente, M; Ponzoni, M; Valsecchi, R | 1 |
| Grant, S | 1 |
| Jin, J; Li, F; Lu, Y; Mai, W; Meng, H; Mu, Q; Pei, R; Qian, W; Tong, H; Yu, M; Zhao, X | 1 |
| Cai, YD; Chen, L; Huang, T; Kong, X; Yang, J; Zheng, M | 1 |
| Chen, SJ; Chen, Z; Mi, JQ; Yan, XJ; Zhou, GB | 1 |
| Allen, SL; Altman, JK; Cortes, JE; Coutre, S; Di Bona, E; Kantarjian, H; Lo-Coco, F; Ravandi, F; Sanford, D; Sanz, MA; Wetzler, M | 1 |
| Barnes, G; Kruse, M; Lo-Coco, F; Martin, M; Mueller, U; Pathak, A; Wildner, R | 1 |
| Chen, B; Chen, C; Chen, L; Chen, SJ; Chen, Z; Fu, YK; Gu, ZH; Hu, J; Jin, J; Li, JM; Lou, YJ; Mi, JQ; Shen, Y; Shen, ZX; Shi, JY; Wang, ZY; Zhao, WL; Zhu, HH; Zhu, HM; Zhu, YM | 1 |
| Clarke, KM; Mills, KI; Young, CS | 1 |
| Barnes, G; Kruse, M; Lo-Coco, F; Martin, M; Mueller, U; Tallman, M; Tang, B; Wildner, R | 1 |
| Bowen, D; Burnett, AK; Clark, RE; Friis, L; Grech, A; Grimwade, D; Hills, RK; Hunter, A; Jones, G; Kell, J; Khwaja, A; Knapper, S; Lok, J; McMullin, MF; Morgan, YG; Russell, NH | 1 |
| Kantarjian, H; Ravandi, F | 1 |
| Han, S; Huang, XJ; Jiang, H; Jiang, Q; Liang, GW; Shi, LW; Zhu, HH | 1 |
| Cottone, F; Efficace, F; Lo Coco, F; Mandelli, F; Platzbecker, U | 1 |
| Aviram, A; Klein, A; Muchtar, E; Oniashvili, N; Parnes, D; Raanani, P; Rabizadeh, E; Shepshelovich, D; Yeshaya, J | 1 |
| Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gómez-De León, A; González-Leal, XJ; Gutiérrez-Aguirre, H; Jaime-Pérez, JC; Pinzón-Uresti, MA | 1 |
| Ren, YQ; Wang, LL | 1 |
| Matsushita, H | 1 |
| Ablain, J; de Thé, H; Esnault, C; Lehmann-Che, J; Poirot, B | 1 |
| Kolb, EA; Meshinchi, S | 1 |
| Adès, L; Alex, AA; Chomienne, C; Fenaux, P; Ganesan, S; Gorombei, P; Guerenne, L; Krief, P; Mathews, V; Omidvar, N; Padua, RA; Patel, S; Pla, M; Schlageter, MH; West, R | 1 |
| Khadwal, A; Malhotra, P; Saikia, UN; Yanamandra, U | 1 |
| Adachi, K; Honma, Y; Kawakami, K; Miyake, T; Suzumiya, J; Takahashi, T | 1 |
| Gerber, JM; Grunwald, MR; Lipford, EH; McDonnell, MH; Smith, ET | 1 |
| Li, D; Luo, D; Wu, S; Zhang, Y; Zhou, J | 1 |
| Hu, L; Huang, L; Li, C; Meng, F; Tang, Y; Wan, K; Wang, Y; Xu, D; Zhou, J | 1 |
| Altman, JK; Norsworthy, KJ | 1 |
| Himeno, S; Sumi, D; Suzukawa, K | 1 |
| Lo-Coco, F; Testa, U | 1 |
| Assaf, C; Beyer, M; Cosagarea, I; Möbs, M; Touba, R; Vandersee, S | 1 |
| Di Donato, L; Lo-Coco, F; Schlenk, RF | 1 |
| Albano, F; Alfonso, V; Amadori, S; Avvisati, G; Breccia, M; Cerqui, E; Ciardi, C; Cicconi, L; Di Bona, E; Divona, M; Ferrantini, A; Ferrara, F; Kropp, MG; Lavorgna, S; Levis, A; Lo-Coco, F; Mandelli, F; Ottone, T; Paoloni, F; Piciocchi, A; Santoro, A; Sborgia, M; Sica, S; Voso, MT | 1 |
| Afroze, D; Azad, NA; Aziz, SA; Baba, SM; Dar, FA; Jan, A; Pandith, AA; Shah, ZA | 1 |
| Atashrazm, F; Dickinson, JL; Holloway, AF; Lowenthal, RM; Woods, GM | 1 |
| Jin, J; Liu, L; Lou, Y; Ma, Y | 1 |
| Albano, F; Amadori, S; Avvisati, G; Borlenghi, E; Brandts, CH; Breccia, M; Brossart, P; Cairoli, R; Cicconi, L; Cortelezzi, A; D'Arco, AM; Di Bona, E; Di Renzo, N; Divona, M; Döhner, H; Döhner, K; Efficace, F; Ehninger, G; Fabbiano, F; Fazi, P; Ferrara, F; Fiedler, W; Fozza, C; Frairia, C; Ganser, A; Hänel, M; Hertenstein, B; La Nasa, G; Link, H; Lo-Coco, F; Lübbert, M; Mandelli, F; Melillo, L; Paoloni, F; Platzbecker, U; Pogliani, EM; Rambaldi, A; Röllig, C; Salih, HR; Sborgia, M; Schlenk, RF; Schmitz, N; Thiede, C; Vignetti, M; Wattad, M | 1 |
| Béné, MC; Bonnet, A; Chevallier, P; Garandeau, C; Garnier, A; Guillaume, T; Houreau-Langlard, D; Hourmant, M; Le Gouill, S; Moreau, P; Peterlin, P; Tissot, A; Vantyghem, S | 1 |
| Chen, SJ; Huang, XJ; Jin, J; Li, JY; Ma, J; Wang, JX; Wu, DP; Zhu, HH | 1 |
| Cai, Y; Chen, W; Du, X; Huang, J; Lou, J; Sun, M; Wang, Z; Zhang, Q | 1 |
| Aoki, A; Hiromori, Y; Ido, A; Kimura, T; Nagase, H; Nakanishi, T | 1 |
| Angelopoulou, MK; Asimakopoulos, JV; Kelepesis, G; Konstantopoulos, K; Koutsi, C; Meletis, J; Papageorgiou, L; Petevi, K; Plata, E; Tsaftaridis, P; Vassilakopoulos, TP | 1 |
| Bochennek, K; Creutzig, U; Dworzak, MN; Faber, J; Flotho, C; Graf, N; Kontny, U; Mueller, JE; Reinhardt, D; Rossig, C; Schmid, I; von Neuhoff, C; von Neuhoff, N; von Stackelberg, A | 1 |
| Gnadler, M; Hecht, A; Lengfelder, E; Mezger, J | 1 |
| Huang, F; Ling, X; Ren, G; Su, Y; Xie, P; Xu, L; Zeng, Z; Zhang, W; Zhang, XK; Zhou, H | 1 |
| Pan, J; Zhang, X | 1 |
| Gao, N; Li, XZ; Sun, JR; Wang, XX; Yu, WZ | 1 |
| Chavda, SJ; Koh, M; Lindsay, S; Willis, F | 1 |
| Dunoyer-Geindre, S; Kruithof, EKO; Lecompte, T; Rivier-Cordey, AS; Tsopra, O | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Guan, W; Jing, Y; Li, WJ; Yang, L; Yu, L | 1 |
| Chen, J; Dai, J; Guo, H; Liu, X; Yan, L; Yu, S; Zhang, W; Zhu, J | 1 |
| Chen, B; Fu, JY; Hou, JX; Wu, LY; Zhang, YM | 1 |
| Chen, S; Lv, X; Yu, J; Zhang, L | 1 |
| Federzoni, EA; Humbert, M; Tschan, MP | 1 |
| Coombs, CC; Mathews, SP | 1 |
| Brossart, P; Gembruch, U; Giovannini, G; Janzen, V; Mayer, K; Merz, WM; Nellessen, CM | 1 |
| Chen, Z; de Thé, H; Pandolfi, PP | 1 |
| Chen, C; Huang, JB; Liu, ZL; Wang, J; Xu, HG; Xue, HM; Zhang, BH | 1 |
| Fang, LW; Hu, NB; Li, B; Pan, LJ; Qin, TJ; Qu, SQ; Xiao, ZJ; Xu, ZF; Zhang, HL; Zhang, Y | 1 |
| Balme, B; Carlioz, V; Collinge, E; Gerland, LM; Paubelle, E; Salles, G; Sujobert, P; Thomas, X; Tigaud, I | 1 |
| Bøe, SO; Eriksson, J; Lång, A; Lång, E; Rowe, AD; Øye, A | 1 |
| Balasubramanian, P; Goni, D; Malhotra, P; Nampoothiri, RV | 1 |
| Jia, JS; Lai, YY; Liu, YR; Qin, YZ; Zhao, XS; Zhu, HH | 1 |
| Cai, Z; Fan, J; He, Q; Huang, W; Wang, Z | 1 |
| Chen, LM; Gong, S; Liu, X; Liu, Y; Wang, HY; Wang, MC; Xi, JY; Zhang, HY; Zhang, XX | 1 |
| Alfonso, V; Breccia, M; Cicconi, L; Diverio, D; Divona, M; Foa, R; Franceschini, L; Iaccarino, L; Latagliata, R; Lo-Coco, F; Molica, M; Ottone, T; Rizzo, M; Voso, MT | 1 |
| Chen, M; Gan, LG; Li, LW; Liu, BZ; Liu, L; Shan, ZL; Xiao, CL; Xu, T; Yao, SF; Zhao, Y; Zhong, L | 1 |
| Levis, M | 2 |
| Jin, J; Lou, Y; Mao, L; Tong, H; Wei, J; Xu, W; Yu, W | 1 |
| Eskazan, AE; Yilmaz, U | 1 |
| Gong, BF; Gong, XY; Li, Y; Lin, D; Liu, BC; Liu, KQ; Liu, YT; Mi, YC; Wang, JX; Wang, Y; Wei, H; Wei, SN; Zhang, GJ; Zhou, CL | 1 |
| Chen, Y; Lantz, RC; Liang, W; Liu, F; Liu, Y; Zhu, J; Zhu, L | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Fan, C; Jiang, H; Jin, J; Lou, Y; Lu, Y; Ma, Y; Wang, Y; Ye, X | 1 |
| Cangini, D; Cerchione, C; Ghelli Luserna Di Rorà, A; Giannini, MB; Gottardi, M; Martinelli, G; Padella, A; Simonetti, G; Sperotto, A | 1 |
| Ji, L; Jiang, Y | 1 |
| Baron, J; Freyer, CW; Luger, SM; Man, Y; Peterson, CE; Przespolewski, A | 1 |
| Yokoyama, Y | 1 |
| Breccia, M | 1 |
| Gang, EJ; Le, J; Li, SY; Liu, HC; Lu, Y; Pei, RZ; Qian, SY; Si, T; Tang, SH | 1 |
| Pemmaraju, N | 1 |
| Baer, MR; DeZern, A; Duong, VH; Emadi, A; Gehrie, E; Ghiaur, G; Gojo, I; Hambley, B; Hickey, E; Kashanian, S; Levis, MJ; Li, A; Newman, MJ; Smith, BD; Varadhan, R; Zacholski, K | 1 |
| Costa, LJ; Dhir, A; Jamy, OH; Xavier, AC | 1 |
| Alex, AA; Balasubramanian, P; Balasundaram, N; Chendamarai, E; David, S; Ganesan, S; Janet, NB; Korula, A; Krishna, S; Kulkarni, U; Kumar, SP; Mathews, V; Palani, HK; Radhakrishnan, NR; Venkatraman, A; Yasar, M | 1 |
| Allen, S; Budman, D; Calabro, A; Devoe, C; Dhingra, R; Ghiuzeli, CM; Saunders, J; Stýblo, M | 1 |
| Ammatuna, E; Diepstra, A; Hazenberg, CLE; Huls, GA; Santing, M | 1 |
| Saitoh, Y; Serizawa, S; Shinohara, M; Shiraiwa, R; Yago, K | 1 |
| Hayakawa, A; Horibe, K; Iijima-Yamashita, Y; Kato, M; Kiyotani, C; Matsumoto, K; Osumi, T; Shioda, Y; Terashima, K; Tomizawa, D; Yamada, Y | 1 |
| Jin, J; Naranmandura, H; Wang, HF; Wang, QQ; Zhao, JZ; Zhu, HH | 1 |
| Chen, YQ; Huang, DP; Huang, LB; Li, Y; Liang, C; Liao, LH; Luo, JS; Luo, XQ; Mai, HR; Tang, YL; Wang, LN; Yang, LH; Ye, ZL; Zhang, XL | 1 |
| Yanada, M | 1 |
| Korsos, V; Miller, WH | 1 |
| Chen, K; Chen, W; Clode, P; Guagliardo, P; Huang, S; Jiang, H; Leung, JK; Song, W; Xu, J; Young, SG | 1 |
| Bunce, CM; Drayson, MT; Khanim, FL | 1 |
| Chen, SN; Huang, J; Jin, J; Li, L; Li, ZY; Lou, LJ; Lou, YJ; Lu, Y; Ma, YF; Mao, LP; Meng, HT; Qian, JJ; Sun, CH; Wang, HY; Wei, JY; Wu, Q; Xu, GX; Xu, JY; Yan, XY; Yang, M; Yu, WJ; Zhu, HH; Zhu, XL | 1 |
| Chen, X; Jia, Y; Liu, Y; Zhang, M | 1 |
| Wiernik, PH | 1 |
| Chen, LM; Gong, S; He, PC; Li, GH; Liu, HB; Liu, L; Lu, XH; Qin, WW; Wald, DN; Wang, HY; Wang, MC; Wei, SH; Xi, JY; Yao, YZ; Zhang, CS; Zhang, HY; Zhang, M; Zhang, XX; Zheng, YS; Zhu, HH | 1 |
| Das, C; Das, R; Jain, A; Jandial, A; Jindal, N; Karunakaran, P; Khadwal, A; Kumar, SR; Lad, D; Malhotra, P; Naseem, S; Prakash, G; Saini, N; Singh, C; Varma, N; Varma, S; Yanamandra, U | 1 |
| Cabrera, HB; Galvis, CC; Regino, CA; Sanz, MÁ; Torres, JD | 1 |
| He, J; Li, W; Lu, D; Lu, P; Shi, Y; Su, Y; Wu, S; Yang, J; Zhang, G; Zhang, M; Zhang, X | 1 |
| Duan, X; Liu, B; Yang, M | 1 |
| Dai, B; Gao, W; Hu, J; Li, J; Li, K; Li, Y; Wang, F; Wang, L; Wang, Y; Zhang, T; Zhao, L; Zhu, H; Zhu, J | 1 |
| Balajthy, Z; Botó, P; Czimmerer, Z; Fésüs, L; Jambrovics, K; Kolostyák, Z; Pap, A; Sarang, Z; Szatmari, I; Uray, IP | 1 |
| Bajel, A; Blombery, PA; Chan, KL; Dun, K; Nedumannil, R; Ng Liet Hing, M; Nguyen, T; Ninkovic, S; Ryland, GL; Tiong, IS; Westerman, DA | 1 |
| Abraham, A; Balasubramanian, P; Fouzia, NA; George, B; Kulkarni, UP; Lionel, S; Mani, T; Mathews, V; Nair, SC; Selvarajan, S | 1 |
| Balajthy, Z; Jambrovics, K; Póliska, S; Scholtz, B; Uray, IP | 1 |
| Bachiashvili, K; Bathini, S; Bhatia, R; Choi, JK; Dunn-Valadez, S; Godby, K; Goyal, G; Jamy, O; Mehta, A; Mikhail, FM; Morlote, D; Oliver, JD; Purdy, KE; Rangaraju, S; Reddy, VB; Vachhani, P; Worth, S | 1 |
| Chen, B; Chen, LX; Dong, HB; He, J; Jiang, RR; Liu, JW; Ou-Yang, J; Yuan, CY; Zeng, H; Zhang, Q; Zhang, QG; Zhou, M | 1 |
| Chen, GH; Chen, HQ; Chen, YQ; Fan, Z; Feng, XQ; Guo, BY; Huang, DP; Huang, LB; Lan, HK; Li, B; Li, WL; Li, Y; Liang, C; Liu, RY; Luo, JS; Luo, XQ; Mai, HR; Tang, YL; Wan, WQ; Wang, LN; Yang, LC; Yang, LH; Zhang, XL; Zhen, ZJ; Zhou, DH | 1 |
125 review(s) available for arsenic and tretinoin
| Article | Year |
|---|---|
Retinoic acid and arsenic: towards oncogene-targeted treatments of acute promyelocytic leukaemia.
Topics: Animals; Arsenic; Artificial Gene Fusion; Cell Transformation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin; Tumor Suppressor Proteins | 1997 |
[Arsenic and retinoic acid, towards targeted treatments of acute promyelocytic leukemia?].
Topics: Antineoplastic Agents; Arsenic; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 1998 |
[Arsenic and retinoic acid, toward targeted treatments of acute promyelocytic anemia?].
Topics: Antineoplastic Agents; Arsenic; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin; Tumor Suppressor Proteins | 1998 |
Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Benzoates; Biomarkers, Tumor; Cheilitis; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Hypercholesterolemia; Hypertriglyceridemia; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Pilot Projects; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Treatment Outcome; Tretinoin; Tumor Cells, Cultured | 1998 |
[Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 1999 |
[Arsenic efficient in acute promyelocytic leukemia].
Topics: Antineoplastic Agents; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 1999 |
[Recent advances of differentiation-inducing therapy for leukemia].
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Histone Deacetylase Inhibitors; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Transcription, Genetic; Tretinoin | 2000 |
Arsenicals and inhibitors of histone deacetylase as anticancer therapy.
Topics: Acetylation; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; China; Chromatin; Drug Evaluation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Melarsoprol; Neoplasm Proteins; Neoplasms; Nervous System Diseases; Oxides; Phenylbutyrates; Protein Processing, Post-Translational; Salvage Therapy; Tretinoin | 1999 |
Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Child; Disease Models, Animal; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2000 |
Acute progranulocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Prognosis; Salvage Therapy; Survival Analysis; Tretinoin | 2001 |
Mouse models of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic; Chromosome Deletion; Disease Models, Animal; Leukemia, Promyelocytic, Acute; Mice; Models, Biological; Mutation; Neoplasm Proteins; Oncogene Proteins, Fusion; Tretinoin | 2001 |
Histone deacetylases and transcriptional therapy with their inhibitors.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Mice; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription, Genetic; Tretinoin | 2001 |
APL, a model disease for cancer therapies?
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Nucleus; Cellular Senescence; Humans; Inclusion Bodies; Leukemia, Promyelocytic, Acute; Multigene Family; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin | 2001 |
Arsenic trioxide, a therapeutic agent for APL.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Disease Models, Animal; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Mice; Mitochondria; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Remission Induction; Survival Rate; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2001 |
Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission.
Topics: Animals; Arsenic Trioxide; Arsenicals; Binding Sites; Caspases; Cell Differentiation; Cysteine Endopeptidases; Humans; Leukemia, Promyelocytic, Acute; Multienzyme Complexes; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Proteasome Endopeptidase Complex; Protein Structure, Tertiary; Remission Induction; Tretinoin | 2001 |
Acute promyelocytic leukemia: evolving therapeutic strategies.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Remission Induction; Tretinoin | 2002 |
Advances in the treatment of relapsed acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Recurrence; Tretinoin | 2002 |
Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenicals; Cell Differentiation; Hemorrhagic Disorders; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Tretinoin | 2000 |
Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Oxides; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tretinoin | 2002 |
Introduction.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Tretinoin | 2002 |
Liposomal-all-trans-retinoic acid in treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Clinical Trials as Topic; Drug Carriers; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Liposomes; Oxides; Tretinoin | 2002 |
Management of acute promyelocytic leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Daunorubicin; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Tretinoin | 2002 |
[Molecular basis of arsenic action in promyelocytic leukemia cells].
Topics: Animals; Apoptosis; Arsenic; Cell Cycle; Humans; Leukemia, Promyelocytic, Acute; Mutation; Neoplasm Proteins; Neutrophils; Nuclear Proteins; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2002 |
Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Combined Modality Therapy; Europe; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Regression, Spontaneous; Oxides; Practice Guidelines as Topic; Risk Factors; Tretinoin; United States | 2003 |
Targeted therapies for the treatment of leukemia.
Topics: Alemtuzumab; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Dose-Response Relationship, Drug; Drug Interactions; Gemtuzumab; Humans; Imatinib Mesylate; Leukemia; Nurse-Patient Relations; Nurse's Role; Oncology Nursing; Oxides; Patient Education as Topic; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Tretinoin | 2003 |
[Expanding possibilities, strategic considerations, and novel methods in the diagnosis and chemotherapy of adult acute myeloid leukemia].
Topics: Adult; Anthracyclines; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oxides; Palliative Care; Prognosis; Remission Induction; Tretinoin | 2003 |
[Recent advances in the treatment of acute myelogenous leukemia: a view of the new agents].
Topics: Alkyl and Aryl Transferases; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cyclosporine; Cytarabine; Daunorubicin; Drug Design; Farnesyltranstransferase; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Nucleosides; Oxides; Prognosis; Radioisotopes; Remission Induction; Tetrahydronaphthalenes; Topoisomerase Inhibitors; Tretinoin; Verapamil | 2003 |
The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Delivery Systems; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2004 |
Acute promyelocytic leukemia as a paradigm for targeted therapy.
Topics: Arsenic Trioxide; Arsenicals; Drug Delivery Systems; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2004 |
An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Treatment Outcome; Tretinoin | 2004 |
Arsenic trioxide in the treatment of haematological malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Oxides; Remission Induction; Salvage Therapy; Tretinoin | 2004 |
Retinoic acid and arsenic for treating acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2005 |
Acute promyelocytic leukemia: a model of molecular target based therapy.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Delivery Systems; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2005 |
Treatment concepts of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Recurrence; Risk Factors; Stem Cell Transplantation; Thrombosis; Translocation, Genetic; Transplantation, Homologous; Tretinoin | 2005 |
Strategies for the treatment of acute promyelocytic leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2006 |
[Therapeutic strategies for patients with relapsed acute promyelocytic leukemia].
Topics: Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Recurrence; Remission Induction; Tetrahydronaphthalenes; Tretinoin | 2006 |
Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.
Topics: Anthracyclines; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cardiovascular Diseases; Heart Diseases; Humans; Interferons; Interleukin-2; Neoplasms; Oxides; Stilbenes; Tretinoin | 2006 |
Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Tretinoin | 2006 |
The design of selective and non-selective combination therapy for acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2007 |
Relationship between cytokines and leukocytosis in patients with APL induced by all-trans retinoic acid or arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytokines; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Tretinoin | 2006 |
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2007 |
Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Topics: Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2007 |
Targeting transcription factors in acute leukemia in children.
Topics: Acute Disease; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; DNA Methylation; Drug Delivery Systems; Histone Deacetylase Inhibitors; Humans; Leukemia; Oxides; Transcription Factors; Tretinoin | 2007 |
Long-term remission of extramedullary relapse from acute promyelocytic leukemia after treatment with arsenic trioxide, intrathecal chemotherapy, and brain irradiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cranial Irradiation; Daunorubicin; Ear Neoplasms; Humans; Injections, Spinal; Leukemia, Myelomonocytic, Acute; Male; Oxides; Radiography; Remission Induction; Sarcoma, Myeloid; Tretinoin | 2007 |
Leukemia, an effective model for chemical biology and target therapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Dasatinib; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tretinoin | 2007 |
From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Disease Models, Animal; Humans; Imatinib Mesylate; Leukemia; Oxides; Piperazines; Pyrimidines; Tretinoin | 2007 |
PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tetrahydronaphthalenes; Tretinoin | 2007 |
Acute promyelocytic leukemia: from highly fatal to highly curable.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2008 |
The expanding role of arsenic in acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2008 |
[Selected mechanisms of the therapeutic effect of arsenic trioxide in cancer treatment].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Caspases; Drug Therapy, Combination; Glutathione; Humans; Intercellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; Neoplasms; NF-kappa B; Oxides; Tretinoin | 2008 |
What is the role of arsenic in newly diagnosed APL?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2008 |
Molecular genetic pathways as therapeutic targets in acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Division; Chromosome Aberrations; Genetic Markers; Humans; Karyotyping; Leukemia, Myeloid, Acute; Models, Genetic; Mutation; Oxides; Proto-Oncogene Proteins c-kit; Transcription, Genetic; Tretinoin | 2008 |
Transcriptome and proteome analyses of drug interactions with natural products.
Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Drug Discovery; Drug Synergism; Gene Expression Profiling; Herb-Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Proteome; Pyrimidines; Tretinoin | 2008 |
Differentiation therapy of acute myeloid leukemia: past, present and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Sensitivity and Specificity; Tretinoin | 2009 |
Beneficial and adverse effects of molecularly targeted therapies for acute promyelocytic leukemia in central nervous system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Central Nervous System Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2009 |
Acute promyelocytic leukemia in childhood.
Topics: Anthracyclines; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Translocation, Genetic; Tretinoin | 2009 |
[Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Tretinoin | 2009 |
Acute promyelocytic leukemia: what are the treatment options?
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Secondary Prevention; Tretinoin | 2010 |
Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Dyspnea; Fever; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Models, Biological; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Transcription, Genetic; Treatment Outcome; Tretinoin | 2010 |
The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Survival; Cell Transformation, Neoplastic; Glutamates; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Myeloid Progenitor Cells; Neoplastic Stem Cells; Nuclear Proteins; Oxides; Prodrugs; Promyelocytic Leukemia Protein; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2010 |
Modern approaches to treating acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2011 |
Differentiation syndrome in patients with acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Glucocorticoids; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Oxides; Risk Factors; Syndrome; Time Factors; Tretinoin | 2012 |
Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Humans; Leukemia, Promyelocytic, Acute; Survival Analysis; Tretinoin | 2011 |
The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Clinical Trials as Topic; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Tretinoin; Young Adult | 2011 |
Advances in therapies for acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Clinical Trials as Topic; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Multicenter Studies as Topic; Oncogene Proteins, Fusion; Oxides; Risk; Salvage Therapy; Tretinoin | 2011 |
[All-trans retinoic acid and arsenic trioxide: their molecular mechanisms of action and updated clinical progress in APL therapy].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin | 2011 |
Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2011 |
Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2011 |
Current treatment strategy of acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Secondary Prevention; Survival Rate; Tretinoin | 2011 |
Pathogenesis and treatment of leukemia: an Asian perspective.
Topics: Arsenic Trioxide; Arsenicals; Asian People; Cell Proliferation; Humans; Leukemia; Leukemia, Large Granular Lymphocytic; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2012 |
[Current treatment of acute myeloid leukaemia in adults].
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin | 2012 |
How to manage acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Central Nervous System Neoplasms; Consolidation Chemotherapy; Drug Synergism; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Oxides; Recurrence; Tretinoin | 2012 |
Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease.
Topics: Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2012 |
Bleeding and thrombosis in acute promyelocytic leukemia.
Topics: Antifibrinolytic Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Tests; Clinical Trials as Topic; Combined Modality Therapy; Cysteine Endopeptidases; Disseminated Intravascular Coagulation; Factor VIIa; Factor VIII; Fibrinogen; Fibrinolysis; Hemorrhage; Heparin; Humans; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm Proteins; Oxides; Plasma; Platelet Count; Platelet Transfusion; Recombinant Proteins; Thromboplastin; Thrombosis; Treatment Failure; Tretinoin | 2012 |
Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Core Binding Factor Alpha 2 Subunit; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic; Tretinoin; Tumor Cells, Cultured | 2012 |
The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies.
Topics: Animals; Antineoplastic Agents; Arsenic; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxidative Stress; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Small Ubiquitin-Related Modifier Proteins; Tretinoin | 2012 |
Provocative pearls in diagnosing and treating acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Arsenic Trioxide; Arsenicals; Biopsy, Fine-Needle; Bone Marrow; Clinical Trials as Topic; Dexamethasone; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Prognosis; Pulmonary Edema; Remission Induction; Respiratory Insufficiency; Tretinoin | 2012 |
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Tretinoin | 2013 |
Management of elderly patients with acute promyelocytic leukemia: progress and problems.
Topics: Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Disease Management; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2013 |
Acute promyelocytic leukemia: do we have a new front-line standard of treatment?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Remission Induction; Tretinoin | 2013 |
Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2014 |
Biology and management of therapy-related acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Early Diagnosis; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Retrospective Studies; Risk Factors; Tretinoin | 2013 |
Postconsolidation maintenance and monitoring in patients with acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Monitoring, Physiologic; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Tretinoin | 2013 |
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Remission Induction; Signal Transduction; Transcriptional Activation; Tretinoin | 2013 |
[Acute promyelocytic leukemia--modern approach to disease pathogenesis and differentiation treatment].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Secondary Prevention; Survival Rate; Tretinoin | 2013 |
ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia?
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Standard of Care; Treatment Outcome; Tretinoin | 2014 |
How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.
Topics: Adult; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Premedication; Syndrome; Tretinoin | 2014 |
Contemporary treatment of APL.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2014 |
What is the standard regimen for patients with acute promyelocytic leukemia?
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Oxides; Practice Guidelines as Topic; Tretinoin | 2014 |
Advanced progress on the relationship between RA and its receptors and malignant tumors.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Neoplastic Cells, Circulating; Oxides; Receptors, Retinoic Acid; Signal Transduction; Tretinoin | 2014 |
Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Disease Models, Animal; DNA End-Joining Repair; Drug Synergism; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin | 2014 |
The coagulopathy in acute promyelocytic leukaemia--what have we learned in the past twenty years.
Topics: Annexin A2; Anticoagulants; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Blood Coagulation Tests; Carboxypeptidase B2; Disseminated Intravascular Coagulation; Fibrinolysis; Forecasting; Granulocyte Precursor Cells; Hemorrhagic Disorders; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recombinant Proteins; Risk Factors; S100 Proteins; Thrombomodulin; Thrombophilia; Thromboplastin; Tretinoin; Urokinase-Type Plasminogen Activator | 2014 |
Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Topoisomerase II Inhibitors; Transcription, Genetic; Tretinoin | 2014 |
Conventional induction and post-remission therapy in APL: have we arrived?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Consolidation Chemotherapy; Daunorubicin; Harringtonines; Homoharringtonine; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Mitoxantrone; Multicenter Studies as Topic; Oxides; Remission Induction; Tretinoin | 2014 |
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Factors; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Hydroxyurea; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Oxides; Platelet Transfusion; Practice Guidelines as Topic; Remission Induction; Risk Assessment; Thioguanine; Treatment Outcome; Tretinoin | 2014 |
Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Cell Differentiation; Clinical Trials as Topic; Disease Management; Drug Monitoring; Drug Resistance, Neoplasm; Historically Controlled Study; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocytosis; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Real-Time Polymerase Chain Reaction; Remission Induction; Salvage Therapy; Tretinoin | 2014 |
Extramedullary disease in APL: a real phenomenon to contend with or not?
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cerebral Hemorrhage; Humans; Incidence; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Models, Biological; Multicenter Studies as Topic; Organ Specificity; Oxides; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Tetrahydronaphthalenes; Tretinoin | 2014 |
Treatment of paediatric APL: how does the therapeutic approach differ from adults?
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Age of Onset; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blood Coagulation Disorders; Bone Marrow Examination; Cell Differentiation; Child; Child, Preschool; Heart Diseases; Humans; Infant; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm, Residual; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Oxides; Prognosis; Pseudotumor Cerebri; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Salvage Therapy; Tretinoin | 2014 |
Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Salvage Therapy; Tretinoin | 2014 |
Acute promyelocytic leukemia in children and adolescents.
Topics: Antineoplastic Agents; Arsenic; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Survival Rate; Translocation, Genetic; Tretinoin | 2014 |
Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: a TRAnsition to targeted therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Treatment Outcome; Tretinoin | 2015 |
New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease Management; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Tretinoin | 2014 |
[Treatment for acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Clinical Trials, Phase III as Topic; Consolidation Chemotherapy; Disseminated Intravascular Coagulation; Gene Fusion; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Molecular Targeted Therapy; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Tetrahydronaphthalenes; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2014 |
Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Treatment Outcome; Tretinoin | 2014 |
Acute promyelocytic leukemia: where did we start, where are we now, and the future.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Failure; Tretinoin | 2015 |
Insights into the All-trans-Retinoic Acid and Arsenic Trioxide Combination Treatment for Acute Promyelocytic Leukemia: A Meta-Analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Controlled Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Remission Induction; Risk; Tretinoin | 2015 |
Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; Translational Research, Biomedical; Tretinoin | 2015 |
[Pathogenesis of Acute Promyelocytic Leukemia].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease Models, Animal; Epigenomics; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Mice; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; Transcription, Genetic; Tretinoin | 2015 |
p53 as an Effector or Inhibitor of Therapy Response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; Treatment Outcome; Tretinoin; Tumor Suppressor Protein p53 | 2015 |
Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Clinical Trials as Topic; Down Syndrome; Epigenesis, Genetic; GATA1 Transcription Factor; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Medical Oncology; Molecular Medicine; Mutation; Oxides; ras Proteins; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Tretinoin | 2015 |
Current standard treatment of adult acute promyelocytic leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Early Diagnosis; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Stem Cell Transplantation; Tretinoin | 2016 |
Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Examination; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Disease Progression; Fatal Outcome; Genetic Predisposition to Disease; Humans; In Situ Hybridization, Fluorescence; Isochromosomes; Karyotype; Leukemia, Promyelocytic, Acute; Male; Molecular Diagnostic Techniques; Mutation; Oncogene Proteins, Fusion; Oxides; Phenotype; Predictive Value of Tests; Time Factors; Translocation, Genetic; Treatment Outcome; Tretinoin; Young Adult | 2015 |
Optimal treatment strategies for high-risk acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Disease Management; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Treatment Outcome; Tretinoin | 2016 |
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Topics: Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Chromosome Aberrations; Disseminated Intravascular Coagulation; DNA-Binding Proteins; fms-Like Tyrosine Kinase 3; Hemorrhagic Disorders; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Leukocyte Count; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Prognosis; Risk Factors; Tandem Repeat Sequences; Treatment Outcome; Tretinoin; Tumor Protein p73; Tumor Suppressor Proteins | 2016 |
Current management of newly diagnosed acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Tretinoin | 2016 |
All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2016 |
Successful treatment of acute promyelocytic leukemia in pregnancy with single-agent all-trans retinoic acid.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gestational Age; Humans; Leukemia, Promyelocytic, Acute; Neoadjuvant Therapy; Pregnancy; Pregnancy Complications, Neoplastic; Treatment Outcome; Tretinoin | 2018 |
Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins; Oncogene Proteins, Fusion; Tretinoin; Tumor Suppressor Proteins | 2017 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
Topics: Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Calicheamicins; Chlorides; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Approval; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mice; Middle Aged; Multicenter Studies as Topic; Recurrence; Sialic Acid Binding Ig-like Lectin 3; Tretinoin | 2020 |
Treatment for relapsed acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Treatment Outcome; Tretinoin | 2022 |
How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy.
Topics: Arsenic; Arsenic Trioxide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin; Tumor Suppressor Proteins | 2022 |
Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies.
Topics: Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thalidomide; Translational Research, Biomedical; Tretinoin | 2022 |
Glomerulonephritis Secondary to Acute Promyelocytic Leukemia that Resolved after Induction Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Glomerulonephritis; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2023 |
Refractory acute promyelocytic leukemia with PLZF/RARa rearrangement: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2023 |
41 trial(s) available for arsenic and tretinoin
| Article | Year |
|---|---|
[Chemoprevention in the high incidence area of lung cancer].
Topics: Antineoplastic Agents; Arsenic; Clinical Trials as Topic; Double-Blind Method; Humans; Lung Neoplasms; Mining; Occupational Diseases; Precancerous Conditions; Random Allocation; Retinoids; Tin; Tretinoin | 1989 |
Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Benzoates; Biomarkers, Tumor; Cheilitis; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Hypercholesterolemia; Hypertriglyceridemia; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Pilot Projects; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Treatment Outcome; Tretinoin; Tumor Cells, Cultured | 1998 |
Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Daunorubicin; Drug Screening Assays, Antitumor; Endothelium, Vascular; Female; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thromboplastin; Tretinoin | 1999 |
Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Tretinoin | 1999 |
[An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid].
Topics: Adolescent; Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin | 1999 |
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Statistics, Nonparametric; Survival Rate; Treatment Outcome; Tretinoin | 2003 |
Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Salvage Therapy; Treatment Outcome; Tretinoin | 2003 |
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; In Situ Nick-End Labeling; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Prospective Studies; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Tretinoin; Tumor Cells, Cultured | 2004 |
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Remission Induction; Tretinoin | 2006 |
Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Europe; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Recurrence; Risk Factors; Treatment Outcome; Tretinoin | 2006 |
[Application of all-trans retinoic acid combining chemotherapy and As4S4 in the maintenance treatment of patients with acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Remission Induction; Sulfides; Treatment Outcome; Tretinoin | 2007 |
Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Risk Factors; Thalidomide; Treatment Outcome; Tretinoin | 2008 |
Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Survival Rate; Time Factors; Tretinoin | 2009 |
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Prognosis; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin; Young Adult | 2010 |
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; North America; Oxides; Survival Analysis; Treatment Outcome; Tretinoin; Young Adult | 2010 |
Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; China; Cohort Studies; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Survival Analysis; Tretinoin | 2011 |
Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cytarabine; Daunorubicin; Disease-Free Survival; Dyspepsia; Female; Follow-Up Studies; Headache; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Tretinoin | 2011 |
The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin; Young Adult | 2012 |
Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation, Homologous; Tretinoin | 2012 |
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Treatment Outcome; Tretinoin; Young Adult | 2012 |
[Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2013 |
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Oxides; Thrombocytopenia; Tretinoin; Young Adult | 2013 |
Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Translocation, Genetic; Tretinoin; Young Adult | 2013 |
Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drugs, Chinese Herbal; Female; Fever; Follow-Up Studies; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Liver; Maintenance Chemotherapy; Male; Middle Aged; Oxides; Remission Induction; Sulfides; Treatment Outcome; Tretinoin; Young Adult | 2013 |
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
Topics: Adult; Aged; Aminoglycosides; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dogs; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Mercaptopurine; Methotrexate; Middle Aged; Oncogene Proteins, Fusion; Oxides; Platelet Count; Remission Induction; Risk; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prospective Studies; Quality of Life; Tretinoin | 2014 |
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukapheresis; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytosis; Male; Middle Aged; Oxides; Retrospective Studies; Survival Rate; Tretinoin | 2015 |
Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Pilot Projects; Tretinoin; Young Adult | 2014 |
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Biomarkers, Tumor; Cardiovascular Diseases; Cell Differentiation; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Tretinoin | 2015 |
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Denmark; Female; Humans; Idarubicin; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; New Zealand; Oncogene Proteins, Fusion; Oxides; Quality of Life; Real-Time Polymerase Chain Reaction; Time Factors; Treatment Outcome; Tretinoin; United Kingdom; Young Adult | 2015 |
[Efficacy Analysis of Arsenic Trioxide Combined with All Trans Retinoic Acid for Acute Promyelocytic Leukemia].
Topics: Arsenic Trioxide; Arsenicals; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Tretinoin | 2015 |
PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Humans; Induction Chemotherapy; Italy; Kinetics; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Oxides; Prognosis; Tretinoin; Young Adult | 2016 |
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies; Risk Factors; Treatment Outcome; Tretinoin; Young Adult | 2017 |
Long-term survival of acute promyelocytic leukaemia patients treated with arsenic and retinoic acid.
Topics: Adult; Arsenic; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Remission Induction; Survival Analysis; Tretinoin | 2016 |
Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Models, Biological; Survival Rate; Tretinoin | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
PML-RARA monitoring in newly diagnosed acute promyelocytic leukemia treated with an entirely oral chemotherapy-free postremission approach: A multiple institution experience.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Retrospective Studies; Tretinoin | 2020 |
[Therapies for newly diagnosed acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Japan; Leukemia, Promyelocytic, Acute; Oxides; Prospective Studies; Treatment Outcome; Tretinoin | 2020 |
The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Child; Drugs, Chinese Herbal; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2022 |
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial).
Topics: Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2022 |
Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2023 |
339 other study(ies) available for arsenic and tretinoin
| Article | Year |
|---|---|
The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic.
Topics: Animals; Antibodies, Antinuclear; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autoantigens; Autoimmune Diseases; Cell Differentiation; CHO Cells; Cricetinae; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Transfection; Tretinoin; Tumor Suppressor Proteins | 1996 |
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Adhesion; Cell Division; Cell Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; Humans; Immunophenotyping; Kinetics; Leukemia, Promyelocytic, Acute; Oxides; Phagocytosis; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Subcellular Fractions; Time Factors; Tretinoin; Tumor Cells, Cultured | 1997 |
Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin | 1998 |
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Down-Regulation; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transglutaminases; Tretinoin; Tumor Cells, Cultured | 1998 |
Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Microscopy, Confocal; Oxides; Tretinoin; Tumor Cells, Cultured | 1998 |
Acute promyelocytic leukemia: a curable disease.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Drug Resistance; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Karyotyping; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Recurrence; Research; Rome; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 1998 |
Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Oxides; T-Lymphocytes; Tretinoin; Tumor Cells, Cultured | 1998 |
Application of heavy metal and cytokine for differentiation-inducing therapy in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin; Tumor Cells, Cultured | 1998 |
Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Differentiation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Humans; Kruppel-Like Transcription Factors; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Zinc Finger Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin; Tumor Cells, Cultured | 1999 |
Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic; Cell Differentiation; Drug Screening Assays, Antitumor; Drug Synergism; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Liver; Lung; Mice; Mice, Transgenic; Neoplasm Proteins; Neoplasm Transplantation; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Remission Induction; Spleen; Tretinoin; Tumor Cells, Cultured | 1999 |
Arsenic: a new place?
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 1999 |
Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasms, Second Primary; Oxides; Recurrence; Transplantation, Autologous; Tretinoin | 1999 |
Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Chromosome Banding; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Feeding and Eating Disorders; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Metaphase; Middle Aged; Musculoskeletal Diseases; Oxides; Pain; Polymerase Chain Reaction; Recurrence; Tretinoin | 1999 |
Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Binding Sites; Bone Marrow; Carrier Proteins; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Ligands; Male; Middle Aged; Mutation, Missense; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Point Mutation; Protein Structure, Tertiary; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tretinoin | 1999 |
Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Differentiation; DNA, Neoplasm; Electrophoresis, Agar Gel; Enzyme Precursors; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Microscopy, Electron; Mitochondria; Mutation; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tretinoin; Tumor Cells, Cultured | 2000 |
Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; bcl-Associated Death Protein; bcl-X Protein; Carrier Proteins; Cell Cycle; Cell Differentiation; Cell Division; Drug Resistance, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, SCID; Mice, Transgenic; Neoplasm Proteins; Neoplasm Transplantation; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recombinant Fusion Proteins; Transplantation, Heterologous; Tretinoin; Tumor Cells, Cultured | 2000 |
Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Drug Therapy, Combination; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Male; Oxides; Translocation, Genetic; Tretinoin; Tumor Cells, Cultured | 2000 |
Arsenic trioxide (As2O3) gradually downregulates tissue factor expression without affecting thrombomodulin expression in acute promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Thrombomodulin; Thromboplastin; Transcription, Genetic; Tretinoin; Tumor Cells, Cultured | 2000 |
Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Pregnancy; Tretinoin | 2000 |
Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2000 |
[Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Pleural Effusion; Remission Induction; Treatment Outcome; Tretinoin | 2000 |
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dyspnea; Fever; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Pleural Effusion; Syndrome; Tretinoin | 2000 |
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Translocation, Genetic; Transplantation, Heterologous; Tretinoin | 2000 |
Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytogenetics; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2000 |
Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro.
Topics: Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase Inhibitors; Caspases; Cell Differentiation; Cell Division; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Neoplasm Transplantation; Neuroblastoma; Oxides; RNA, Messenger; Tetrazolium Salts; Thiazoles; Transplantation, Heterologous; Tretinoin; Tumor Cells, Cultured | 2000 |
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Cell Culture Techniques; Cell Differentiation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance; Female; Humans; Leukemia, Experimental; Leukemia, Promyelocytic, Acute; Mice; Mice, SCID; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Survival Rate; Tretinoin | 2001 |
Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Christianity; Cytogenetic Analysis; Drug Therapy, Combination; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Middle Aged; Oxides; Platelet Count; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2000 |
[Tissue factor expression during all-trans retinoic acid or arsenic trioxide treatment in acute promyelocytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Hemostatics; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Thromboplastin; Tretinoin | 1998 |
[In vitro study on arsenic trioxide-induced apoptosis of retinoic acid resistant acute promyelocytic leukemia cell line(MR-2)].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin; Tumor Cells, Cultured | 1998 |
Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Case-Control Studies; Female; Hemorrhage; Hemostasis; Hemostatics; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thromboplastin; Tretinoin | 2001 |
Hot on the TRAIL of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Ligands; Membrane Glycoproteins; Neoplasm Proteins; NF-kappa B; Oncogene Proteins, Fusion; Oxides; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tretinoin; Tumor Necrosis Factor-alpha | 2001 |
Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Coculture Techniques; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Leukemia, Promyelocytic, Acute; Membrane Glycoproteins; Neoplasm Proteins; NF-kappa B; Oncogene Proteins, Fusion; Oxides; Paracrine Communication; Proteins; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; TNF Receptor-Associated Factor 1; TNF-Related Apoptosis-Inducing Ligand; Tretinoin; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2001 |
Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor alpha-positive human T-cell lymphotropic virus type-I-transformed cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Transformed; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; T-Lymphocytes; Tretinoin | 2001 |
Unusual sites of involvement by hematologic malignancies. Case 3. External auditory canal tumor: a rare chloroma in acute promyelocytic leukemia with a complete response to arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Ear Canal; Ear Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin | 2001 |
[Regulation of arsenic trioxide-inducing apoptosis].
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; HL-60 Cells; Humans; Leukemia, Myeloid; Oligopeptides; Oxides; Tretinoin; Tumor Cells, Cultured | 1999 |
Transactivation of RARE and GRE in the cellular response to arsenic.
Topics: Animals; Antineoplastic Agents; Arsenates; Arsenic; Arsenites; Cell Differentiation; Cell Line; Drug Synergism; Epidermal Cells; Fluocinolone Acetonide; Genes, Reporter; Glucocorticoids; Luciferases; Mice; Response Elements; Transcriptional Activation; Transfection; Tretinoin | 2001 |
[Effects of all-trans retinoic acid, arsenic trioxide and daunorubicin on tissue factor expression in NB4 cells].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Daunorubicin; Factor VIII; Humans; Leukemia, Promyelocytic, Acute; Oxides; RNA, Messenger; Thromboplastin; Tretinoin; Tumor Cells, Cultured | 1999 |
Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676).
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Arsenic Trioxide; Arsenicals; Central Nervous System; Combined Modality Therapy; Female; Gemtuzumab; Gene Rearrangement; Genes, MDR; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Oxides; Sialic Acid Binding Ig-like Lectin 3; Translocation, Genetic; Tretinoin | 2001 |
Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Factors; Female; Hemostasis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thromboplastin; Tretinoin | 2000 |
Long-term survey of outcome in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Prognosis; Remission Induction; Time Factors; Treatment Outcome; Tretinoin | 2000 |
[Potentiation of arsenic trioxide-induced apoptosis by retinoic acid in retinoic acid sensitive and resistant HL-60 myeloid leukemia cells].
Topics: Alitretinoin; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Oxides; Tretinoin | 2000 |
[Drug resistance of acute promyelocytic leukemia (APL) to all-trans retinoic acid (ATRA) and its reversion].
Topics: Alprostadil; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Cell Survival; Drug Interactions; Drug Resistance; Harringtonines; HL-60 Cells; Homoharringtonine; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Promyelocytic, Acute; Oxides; Recombinant Proteins; Tretinoin | 2000 |
Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activation of caspase-3.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Caspase 3; Caspases; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Membrane Potentials; Mitochondria; Multiple Myeloma; Oxides; Tretinoin; Tumor Cells, Cultured | 2001 |
Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; RNA, Messenger; Thromboplastin; Tretinoin; Tumor Cells, Cultured | 2001 |
[Mechanisms of arsenic trioxide-induced apoptosis in myeloma cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Division; Dithiothreitol; Drug Interactions; Humans; Interferon-alpha; Multiple Myeloma; Oxides; Tretinoin; Tumor Cells, Cultured | 2001 |
[A study of tissue factor expression and hemostatic molecular markers in patients with acute promyelocytic leukemia].
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Hemostasis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Thromboplastin; Tretinoin | 2001 |
[Effects of arsenic trioxide on K562 cells stably expressing two promyelocytic leukemia-specific fusion proteins].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Differentiation; Cell Division; Gene Expression; Growth Inhibitors; Humans; K562 Cells; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2000 |
[Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Cells, Cultured; Female; Gene Expression; Humans; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; RNA, Messenger; Thromboplastin; Transcription, Genetic; Tretinoin; Tumor Cells, Cultured; U937 Cells | 2000 |
Successful unrelated bone marrow transplantation after arsenic trioxide treatment in a patient with relapsed acute promyelocytic leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Bone Marrow Transplantation; Combined Modality Therapy; Drug Resistance; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Tretinoin | 2002 |
[Mechanism of tissue factor expression on NB4 cells down-regulated by all-trans retinoic acid and arsenic trioxide].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cycloheximide; Dactinomycin; Down-Regulation; Gene Expression Regulation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thromboplastin; Tretinoin; Tumor Cells, Cultured | 2000 |
[Regulation of telomerase activity in HL-60 and NB4 cells by arsenic trioxide].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Size; HL-60 Cells; Humans; Oxides; Proto-Oncogene Proteins c-bcl-2; Telomerase; Time Factors; Tretinoin; Tumor Cells, Cultured | 2000 |
Mechanism of action of all-trans retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Cell Differentiation; Chlorides; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2002 |
Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Tretinoin | 2002 |
Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Monitoring; Electrocardiography; Female; Heart; Heart Diseases; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies; Remission Induction; Tretinoin | 2002 |
Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Immunocompetence; Leukemia, Promyelocytic, Acute; Liposomes; Mice; Mice, Inbred C3H; Mice, SCID; Mice, Transgenic; Neoplasm Proteins; Neoplasm Transplantation; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2002 |
Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
Topics: Acetamides; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Butyrates; Cell Differentiation; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin; Tumor Cells, Cultured | 2002 |
Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator.
Topics: Adolescent; Adult; Annexin A2; Antineoplastic Agents; AraC Transcription Factor; Arsenic Trioxide; Arsenicals; Bacterial Proteins; Female; Fibrinolysin; Gene Expression Regulation; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Plasminogen Activators; Repressor Proteins; RNA, Messenger; Tissue Plasminogen Activator; Transcription Factors; Transfection; Tretinoin; Tumor Cells, Cultured | 2002 |
In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Cyclic AMP; Leukemia, Promyelocytic, Acute; Mice; Mice, Transgenic; Oxides; Signal Transduction; Theophylline; Tretinoin; Tumor Cells, Cultured | 2002 |
Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell lymphoma and gestational trophoblastic disease.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, Mantle-Cell; Male; Neoplasms, Second Primary; Oxides; Pregnancy; Tretinoin | 2002 |
[The expression of Fas, FasL and Bcl-2 on RMA cells during the process of apoptosis induced by chemotherapeutic drugs].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Dexamethasone; Etoposide; Fas Ligand Protein; fas Receptor; Gene Expression; Membrane Glycoproteins; Mice; Oxides; Proto-Oncogene Proteins c-bcl-2; Tretinoin; Tumor Cells, Cultured | 2002 |
[In vitro study of the effects of arsenic trioxide combined with 8-CPT-cAMP on differentiation induction in retinoic acid resistant acute promyelocytic leukemia cells].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cyclic AMP; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thionucleotides; Tretinoin | 2003 |
[Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Gene Expression; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Remission Induction; Time Factors; Treatment Outcome; Tretinoin | 2003 |
[Preliminary observation of the combination of arsenic trioxide and all-trans retinoic acid for the treatment of acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2003 |
Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm, Residual; Oxides; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2003 |
[In vitro study on realgar induced apoptosis of all-trans acid resistant acute promeylocytic leukemia cell line (MR2)].
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Cell Division; Cell Survival; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Materia Medica; Sulfides; Tretinoin; Tumor Cells, Cultured | 2002 |
The cleavage product deltaPML-RARalpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells.
Topics: Acetamides; Antineoplastic Agents; Arsenic; Blotting, Western; Cell Differentiation; Cell Line; Cycloheximide; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Leupeptins; Luciferases; Multienzyme Complexes; Neoplasm Proteins; Oncogene Proteins, Fusion; Plasmids; Proteasome Endopeptidase Complex; Protein Synthesis Inhibitors; Transcriptional Activation; Transfection; Tretinoin; Tumor Cells, Cultured | 2003 |
The history of acute promyelocytic leukaemia.
Topics: Antineoplastic Agents; Arsenic; Chromosome Aberrations; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2003 |
Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Tretinoin | 2003 |
[Change of PML/PML-RARalpha protein during treatment with tetraarsenic tetrasulfide (As4S4) in patients with acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenicals; Female; Fluorescent Antibody Technique, Indirect; Humans; In Situ Nick-End Labeling; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Promyelocytic Leukemia Protein; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2003 |
Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1.
Topics: Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Cell Differentiation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Interferon Regulatory Factor-1; Interferon-gamma; Leukemia, Promyelocytic, Acute; Oxides; Phosphoproteins; Promoter Regions, Genetic; Signal Transduction; STAT1 Transcription Factor; Superoxides; Trans-Activators; Tretinoin; Tumor Cells, Cultured | 2003 |
[Effects of realgar on tissue factor expression of NB4 and MR2 cells].
Topics: Antineoplastic Agents; Arsenicals; Blood Coagulation Factors; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; K562 Cells; Leukemia, Promyelocytic, Acute; Materia Medica; Neoplasm Proteins; RNA, Messenger; Sulfides; Thromboplastin; Tretinoin | 2003 |
Biography of Zhu Chen.
Topics: Arsenic Trioxide; Arsenicals; China; Hematology; History, 20th Century; History, 21st Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2004 |
[Effects of combination therapy with all-trans retinoic acid and arsenic trioxide on acute promyelocytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin | 2004 |
Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide.
Topics: Arsenic Trioxide; Arsenicals; Cell Culture Techniques; Cell Line, Tumor; Cytokines; Drug Resistance, Neoplasm; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Mutation, Missense; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Telomerase; Telomere; Tretinoin | 2004 |
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Middle Aged; Oxides; Recurrence; Tretinoin | 2004 |
Treatment of acute promyelocytic leukemia in children: arsenic or ATRA.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin | 2004 |
Sodium selenite induces apoptosis in acute promyelocytic leukemia-derived NB4 cells by a caspase-3-dependent mechanism and a redox pathway different from that of arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Leukemia, Promyelocytic, Acute; Mitochondria; Oxidation-Reduction; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Sodium Selenite; Sulfhydryl Compounds; Tretinoin | 2004 |
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Bromodeoxyuridine; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Interactions; Humans; Ki-67 Antigen; Kinetics; Leukemia, Myeloid, Acute; Oxides; S Phase; Tretinoin; Tumor Cells, Cultured | 2005 |
[Effects of arsenic trioxide on the subcellular localization of PML/PML-RARalpha protein in leukemic cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; HL-60 Cells; Humans; Intracellular Space; Leukemia; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Protein Transport; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 1997 |
[Effect of arsenic trioxide on drug transporting molecules in acute promyelocytic leukemia cell line].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oxides; Tretinoin; Vault Ribonucleoprotein Particles | 2004 |
PRAM-1 potentiates arsenic trioxide-induced JNK activation.
Topics: Adaptor Proteins, Signal Transducing; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Kinetics; Leukemia, Promyelocytic, Acute; Microfilament Proteins; Oligopeptides; Oxides; Proteins; src Homology Domains; Tretinoin | 2005 |
Retinoic acid and arsenic trioxide cooperate for apoptosis through phosphorylated RXR alpha.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line; Cell Line, Tumor; Dimerization; DNA Primers; Mice; Oxides; Phosphorylation; Plasmids; Retinoid X Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2005 |
Triterpenoid CDDO-Im downregulates PML/RARalpha expression in acute promyelocytic leukemia cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Leukemic; Humans; Imidazoles; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oleanolic Acid; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor alpha; Transcription Factors; Tretinoin; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2005 |
Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bryostatins; Cell Cycle; Cell Line, Tumor; Cell Transformation, Neoplastic; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Macrolides; Myelopoiesis; Oxides; Tretinoin | 2005 |
[Arsenic treatment for leukemia: new model of human cancer target treatment].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Pyrimidines; Tretinoin | 2005 |
Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Computational Biology; Drug Synergism; Electrophoresis, Gel, Two-Dimensional; Gene Expression Regulation, Neoplastic; Granulocytes; Humans; Leukemia, Promyelocytic, Acute; Mass Spectrometry; Oligonucleotide Array Sequence Analysis; Oxides; Proteomics; Reverse Transcriptase Polymerase Chain Reaction; Systems Biology; Tretinoin | 2005 |
Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin; Tumor Cells, Cultured | 2005 |
[Therapeutic effects of combination of arsenic trioxide with low-dose all-trans retinoic acid on induction of remission acute promyeloeytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2005 |
Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Remission Induction; Telomerase; Telomere; Tretinoin; Tumor Cells, Cultured | 2005 |
Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Erythrocyte Count; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytes; Oxides; Platelet Count; Time Factors; Tretinoin | 2005 |
[The impact of arsenic trioxide or all-trans retinoic acid treatment on coagulopathy in acute promyelocytic leukemia].
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Down-Regulation; Female; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Thrombomodulin; Thromboplastin; Tretinoin | 2001 |
Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis in human hepatoma, breast cancer, and lung cancer cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Glutathione; Glutathione Transferase; Humans; Lung Neoplasms; Oxides; Tretinoin | 2005 |
Current management and new approaches in the treatment of APL.
Topics: Aminoglycosides; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Monitoring; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Stem Cell Transplantation; Tretinoin | 2003 |
Hypoxia-simulating agents selectively stimulate arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Cell Hypoxia; Cobalt; Deferoxamine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin; U937 Cells | 2005 |
Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Cell Differentiation; Cell Division; Cell Hypoxia; Cell Line, Tumor; Cobalt; Deferoxamine; Drug Synergism; Gene Expression Regulation, Leukemic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Oxygen; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin; U937 Cells | 2005 |
PLC-beta2 monitors the drug-induced release of differentiation blockade in tumoral myeloid precursors.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Enzyme Induction; Growth Inhibitors; Humans; Myeloid Progenitor Cells; Oxides; Phospholipase C beta; Tretinoin | 2006 |
Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Gene Silencing; HL-60 Cells; Humans; Leukemia; Minor Histocompatibility Antigens; Oxides; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Tretinoin; Up-Regulation | 2006 |
Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Methylation; Oxides; Seafood; Tretinoin | 2006 |
Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Evaluation; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin | 2006 |
Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Combined Modality Therapy; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Radiography; Recurrence; Remission Induction; Sarcoma, Myeloid; Stem Cell Transplantation; Translocation, Genetic; Transplantation, Homologous; Tretinoin | 2006 |
[Long-term survival analysis in 170 cases of acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Prognosis; Proportional Hazards Models; Remission Induction; Retrospective Studies; Survival Analysis; Survival Rate; Tretinoin | 2006 |
Arsenic trioxide-responsive leukemia cutis in a patient with acute promyelocytic leukemia after ATRA treatment.
Topics: Adolescent; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Oxides; Risk; Skin; Tretinoin | 2006 |
Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells.
Topics: Acute Disease; Aquaporins; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Gene Expression Profiling; Humans; K562 Cells; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Oxides; Point Mutation; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Tretinoin; Up-Regulation | 2007 |
A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Tretinoin | 2007 |
Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cardiomyopathies; Drug Therapy, Combination; Echocardiography; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Tretinoin | 2007 |
Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Granulocytes; HL-60 Cells; Humans; Leukemia, Myeloid; Macrophages; Monocytes; Oxides; Protein Transport; Proto-Oncogene Proteins c-akt; RNA-Binding Proteins; RNA, Small Interfering; Tretinoin | 2007 |
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2007 |
Current treatment of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Clinical Trials as Topic; Computer Systems; Disease Management; Drug Monitoring; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Mice; Multicenter Studies as Topic; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Predictive Value of Tests; Recurrence; Sensitivity and Specificity; Transfection; Tretinoin | 2007 |
Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ataxin-1; Ataxins; Biomarkers, Tumor; Cell Division; Cell Line, Tumor; Female; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Nerve Tissue Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Recombinant Fusion Proteins; Transfection; Tretinoin; Tumor Stem Cell Assay | 2007 |
Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; DNA Probes; Humans; Leukemia, Promyelocytic, Acute; NF-kappa B; Oxides; Tretinoin | 2006 |
[Effects of arsenic trioxide or retinoic acid on mRNA and protein expression of tissue factor and thrombomodulin and procoagulant activity in NB4 cells].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; RNA, Messenger; Thrombomodulin; Thromboplastin; Tretinoin; Tumor Cells, Cultured | 2007 |
Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60rho0 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Resistance, Neoplasm; Genes, Mitochondrial; Glycolysis; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2008 |
Advances in management of acute promyelocytic leukemia with arsenic trioxide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2007 |
Role of Myc in differentiation and apoptosis in HL60 cells after exposure to arsenic trioxide or all-trans retinoic acid.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Differentiation; Enzyme-Linked Immunosorbent Assay; Gene Expression; Gene Expression Profiling; HL-60 Cells; Humans; Oxides; Proto-Oncogene Proteins c-myc; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Telomerase; Tretinoin | 2008 |
The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Australia; Base Sequence; Bone Marrow; Chromosome Aberrations; Clinical Trials as Topic; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; DNA Mutational Analysis; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Mutant Chimeric Proteins; Neoplasm Proteins; Oxides; Receptors, Retinoic Acid; Registries; Remission Induction; Retinoic Acid Receptor alpha; RNA, Messenger; Sequence Deletion; Tretinoin | 2007 |
[Effects of arsenic trioxide and ATRA on PLZF-RARalpha-positive U937 leukemic cells].
Topics: Antigens, CD; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Proliferation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Transcription Factors; Leukemia; Nitroblue Tetrazolium; Oxidation-Reduction; Oxides; Promyelocytic Leukemia Zinc Finger Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tetracycline; Tretinoin; U937 Cells | 2007 |
Adhesion molecules and Differentiation Syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Adhesion; Cell Adhesion Molecules; Cell Differentiation; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred BALB C; Mice, Knockout; Neoplasm Proteins; Oxides; Phenylbutyrates; Syndrome; Tretinoin; Tumor Cells, Cultured | 2007 |
Effect of the combination of ATRA, ATO and DNR on CD11b expression in NB4 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; CD11b Antigen; Cell Line, Tumor; Daunorubicin; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2008 |
All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Topics: Adolescent; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Dysplastic Nevus Syndrome; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2008 |
Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; CD11c Antigen; Cell Differentiation; Cyclooxygenase 1; Dinoprostone; Drug Therapy, Combination; Humans; Indomethacin; Leukemia, Promyelocytic, Acute; Models, Biological; Oxides; Tretinoin; Tumor Cells, Cultured | 2008 |
Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Remission Induction; Salvage Therapy; Tretinoin | 2008 |
Retrospective analysis of 65 Chinese children with acute promyelocytic leukemia: a single center experience.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Oxides; Prognosis; Recurrence; Retrospective Studies; Treatment Outcome; Tretinoin | 2008 |
Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Differentiation; Cell Line, Tumor; Eukaryotic Initiation Factor-2; Eukaryotic Initiation Factor-4G; Granulocytes; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oxides; Phosphatidylinositol 3-Kinases; Protein Kinases; Proto-Oncogene Proteins c-akt; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Tretinoin; Up-Regulation | 2008 |
Acute promyelocytic leukemia: recent advances in diagnosis and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Salvage Therapy; Treatment Outcome; Tretinoin | 2008 |
Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Line, Tumor; Gene Expression Regulation, Leukemic; Homeodomain Proteins; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oncogene Proteins, Fusion; RNA, Neoplasm; Transcription, Genetic; Tretinoin | 2009 |
Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Transitional Cell; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasms, Multiple Primary; Oxides; Remission Induction; Tretinoin; Urinary Bladder Neoplasms | 2008 |
Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia.
Topics: Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukemia, Promyelocytic, Acute; Male; Mass Spectrometry; Middle Aged; Oxides; Recurrence; Remission Induction; Time Factors; Tretinoin | 2009 |
Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells.
Topics: alpha-Tocopherol; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Lipid Peroxidation; Oxides; Tretinoin | 2009 |
[Can As2O3 improve the prognosis of childhood acute promyelocytic leukemia?--A single center experience].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oncogene Proteins, Fusion; Oxides; Prognosis; Retrospective Studies; Treatment Outcome; Tretinoin | 2008 |
Curative strategies in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Cytarabine; Daunorubicin; Disease-Free Survival; Growth Inhibitors; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Recurrence, Local; Oxides; Tretinoin | 2008 |
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Polymerase Chain Reaction; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin | 2009 |
[Effect of additional chromosome abnormalities on the outcome of newly diagnosed acute promyelocytic leukemia treated with red arsenic sulfide and all trans-retinoic acid plus anthracyclin based protocol].
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Sulfides; Treatment Outcome; Tretinoin; Young Adult | 2008 |
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Carcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Iodides; Lovastatin; Neoplasm Metastasis; Oxides; Pyrazines; Sirolimus; Thymus Gland; Thyroid Neoplasms; Tretinoin | 2009 |
Curing APL: differentiation or destruction?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2009 |
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
Topics: Aquaporins; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Leukemic; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Prognosis; Survival Rate; Time Factors; Tretinoin | 2009 |
Acute promyelocytic leukemia--weapons of mass differentiation.
Topics: Animals; Antineoplastic Agents; Arsenic; Cell Differentiation; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Tretinoin | 2009 |
[The significance of combined therapy of arsenic trioxide and all-trans retinoic acid in treating acute promyelocytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Retrospective Studies; Tretinoin; Young Adult | 2009 |
[Immunofluorescence examination of CK-13 expression in cell line KB differentiated by all-trans retinoic acid or As2 O3].
Topics: Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Cell Differentiation; Fluorescent Antibody Technique; Humans; KB Cells; Keratin-13; Mouth Neoplasms; Oxides; Tretinoin | 2009 |
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Blood Chemical Analysis; Bone Marrow; Cohort Studies; Confidence Intervals; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Monitoring, Physiologic; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Predictive Value of Tests; Probability; Prognosis; Proportional Hazards Models; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Severity of Illness Index; Survival Analysis; Treatment Outcome; Tretinoin | 2009 |
Arsenic trioxide associated toothache.
Topics: Arsenic Trioxide; Arsenicals; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Toothache; Tretinoin | 2010 |
Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Medical Oncology; Neoplasms, Second Primary; Oxides; Translocation, Genetic; Treatment Outcome; Tretinoin | 2009 |
[Clinical study on the fibrinolytic activity in patients with acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Annexin A2; Arsenic Trioxide; Arsenicals; Female; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Tretinoin; Urokinase-Type Plasminogen Activator; Young Adult | 2009 |
How I treat acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Examination; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Outcome Assessment, Health Care; Oxides; Practice Guidelines as Topic; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2009 |
Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Child; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Myeloablative Agonists; Oncogene Proteins, Fusion; Oxides; Peripheral Blood Stem Cell Transplantation; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Tretinoin; Young Adult | 2009 |
Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome.
Topics: Anti-Inflammatory Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL24; Chemokine CCL7; Chemokines; Dexamethasone; Enzyme-Linked Immunosorbent Assay; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oxides; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; Syndrome; Tretinoin; Tumor Cells, Cultured | 2009 |
Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2009 |
[Apoptosis of MR2 cells induced by Tanshinone II A combined with arsenic trioxide].
Topics: Abietanes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Phenanthrenes; Tretinoin | 2009 |
[Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin; Young Adult | 2009 |
Successful post-remission therapy with a combination of all-trans retinoic acid and arsenic trioxide in an elderly Japanese patient newly diagnosed with acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Asian People; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Tretinoin | 2010 |
Gangrenous cheilitis associated with all-trans retinoic acid therapy for acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biopsy; Cheilitis; Female; Gangrene; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2010 |
Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Blood Coagulation Tests; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Survival; Daunorubicin; Etoposide; Factor Xa; Female; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Male; Membrane Glycoproteins; Microscopy, Confocal; Milk Proteins; Oxides; Phosphatidylserines; Thrombin; Thromboplastin; Tretinoin; Young Adult | 2010 |
Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1.
Topics: Acetylcysteine; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dithiothreitol; Enzyme Activation; Genetic Variation; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase Kinases; Oxides; Phosphorylation; Protein Kinases; Reactive Oxygen Species; RNA, Small Interfering; Tretinoin; U937 Cells | 2010 |
Treatment of therapy related acute promyelocytic leukemia with the combination of all trans retinoic acid and arsenic trioxide without chemotherapy: a series of three patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Choriocarcinoma; Female; Humans; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neuroectodermal Tumors; Ovarian Neoplasms; Oxides; Prognosis; Tretinoin | 2010 |
Comparative proteome study of apoptosis induced by As4S4 in retinoid acid resistant human acute promyelocytic leukemia NB4-R1 cells.
Topics: Apoptosis; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Prohibitins; Proteomics; Signal Transduction; Sulfides; Tretinoin | 2010 |
All-trans retinoic acid and arsenic rescue patients with acute promyelocytic leukemia from a potential 'perfect storm'.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Oxides; Prognosis; Tretinoin | 2010 |
Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oncogenes; Oxides; Tretinoin | 2010 |
Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Child; Child, Preschool; China; Disseminated Intravascular Coagulation; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2010 |
CNS relapse in acute promyeloctyic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Neoplasms; Brain Neoplasms; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cranial Irradiation; Cytarabine; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Mercaptopurine; Methotrexate; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome; Tretinoin; Tumor Suppressor Proteins | 2010 |
Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
Topics: Arsenic Trioxide; Arsenicals; Autophagy; Cell Differentiation; Cell Line, Tumor; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Protein Serine-Threonine Kinases; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; RNA, Small Interfering; Solubility; TOR Serine-Threonine Kinases; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2010 |
Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Differentiation; Cell Proliferation; Drug Synergism; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Mitogen-Activated Protein Kinases; Oncogene Proteins, Fusion; Oxides; Tretinoin; Tumor Cells, Cultured | 2010 |
Autophagic degradation of an oncoprotein.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Proteasome Endopeptidase Complex; Tretinoin | 2010 |
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Radiation-Induced; Oxides; Treatment Outcome; Tretinoin | 2011 |
Arsenic trioxide (As₂O₃) inhibits murine WEHI-3 leukemia in BALB/c mice in vivo.
Topics: Animals; Antigens, Differentiation; Arsenic Trioxide; Arsenicals; B-Lymphocytes; Cell Differentiation; Cell Line, Tumor; Leukemia; Leukemia, Experimental; Macrophages; Male; Mice; Mice, Inbred BALB C; Oxides; Spleen; Tretinoin | 2012 |
Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Survival Rate; Time Factors; Treatment Outcome; Tretinoin; Young Adult | 2011 |
Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Risk Assessment; Treatment Outcome; Tretinoin | 2010 |
Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia.
Topics: Adaptor Proteins, Signal Transducing; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Phenotype; Prognosis; Recurrence; Translocation, Genetic; Tretinoin | 2010 |
The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Annexin A2; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Tests; Blotting, Western; Cell Proliferation; Female; Fibrinolysin; Fibrinolysis; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Plasminogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tissue Plasminogen Activator; Tretinoin; Young Adult | 2011 |
Don't just stand there, do something: strategies for the prevention of early death in acute promyelocytic leukemia: a commentary.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disseminated Intravascular Coagulation; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Secondary Prevention; Survival Rate; Time Factors; Treatment Failure; Tretinoin | 2011 |
[A successful case of tanshinone II A treatment for relapsed acute promyelocytic leukemia after maintainance therapy of all-trans retinoic acid and arsenic trioxide].
Topics: Abietanes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Neoplasm Recurrence, Local; Oxides; Tretinoin; Young Adult | 2010 |
Treatment of acute promyelocytic leukemia for older patients.
Topics: Age Factors; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Prognosis; Treatment Outcome; Tretinoin | 2011 |
Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Prognosis; Recombinant Fusion Proteins; Tretinoin | 2011 |
Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Bone Marrow; Bone Neoplasms; Combined Modality Therapy; Doxorubicin; Drug Resistance, Neoplasm; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Mercaptopurine; Methotrexate; Oxides; Radionuclide Imaging; Remission Induction; Salvage Therapy; Sarcoma, Myeloid; Soft Tissue Neoplasms; Tetrahydronaphthalenes; Tretinoin | 2011 |
[Establishment of two-dimensional electrophoresis proteomic profiles of retinoid acid resistant human acute promyelocytic leukemia NB4-R1 cells with apoptosis induced by realgar].
Topics: Apoptosis; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Humans; Leukemia, Promyelocytic, Acute; Proteome; Sulfides; Tretinoin | 2011 |
Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Cohort Studies; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Iran; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2011 |
[Effects of As2O3 and all-trans retinoic acid on the growth of HeLa cell line and their relation with gene NDRG1].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle Proteins; Cell Proliferation; Dose-Response Relationship, Drug; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tretinoin | 2011 |
Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Developing Countries; Humans; Leukemia, Promyelocytic, Acute; Oxides; Survival Analysis; Tretinoin | 2011 |
Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Treatment Outcome; Tretinoin | 2011 |
(+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo.
Topics: alpha-Tocopherol; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Cytochromes c; Disease Models, Animal; Electron Transport Complex I; Electron Transport Complex II; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Mice; Mice, Transgenic; Mitochondria; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Oxides; Protein Stability; Rats; Reactive Oxygen Species; Transplantation, Isogeneic; Tretinoin | 2012 |
All-trans retinoic acid protects against arsenic-induced uterine toxicity in female Sprague-Dawley rats.
Topics: Animals; Arsenic; Arsenites; Female; Random Allocation; Rats; Rats, Sprague-Dawley; Reproductive Control Agents; Sodium Compounds; Tretinoin; Uterus | 2011 |
Realgar-induced apoptosis and differentiation in all-trans retinoic acid (ATRA)-sensitive NB4 and ATRA-resistant MR2 cells.
Topics: Apoptosis; Arsenicals; Cell Differentiation; Cell Line, Tumor; Disease-Free Survival; DNA, Neoplasm; Gene Expression Profiling; Humans; Leukemia, Promyelocytic, Acute; Microarray Analysis; Oncogene Proteins, Fusion; Signal Transduction; Sulfides; Tretinoin | 2012 |
Promyelocytic leukemia nuclear bodies support a late step in DNA double-strand break repair by homologous recombination.
Topics: Arsenic Trioxide; Arsenicals; Cell Nucleus; DNA Breaks, Double-Stranded; DNA End-Joining Repair; DNA, Neoplasm; Genomic Instability; Histones; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Phosphorylation; Promyelocytic Leukemia Protein; Rad51 Recombinase; Recombinational DNA Repair; RNA Interference; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2012 |
Sustained molecular remission after arsenic trioxide and gemutuzumab ozogamicin in a pediatric patient with relapsed acute promyelocytic leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Benzoates; Child; Drug Administration Schedule; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Tetrahydronaphthalenes; Tretinoin | 2012 |
Long-term remission in a case of acute promyelocytic leukemia patient with marked myelofibrosis treated with arsenic trioxide, all-trans retinoic acid and consolidation therapy with daunorubicin plus cytarabine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Primary Myelofibrosis; Remission Induction; Survivors; Tretinoin | 2012 |
[Regulation of all-trans retinoic acid and arsenic trioxide on CD44v6 expression in NB4 cells].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Gene Expression Regulation, Leukemic; Humans; Hyaluronan Receptors; Leukemia, Promyelocytic, Acute; Oxides; Signal Transduction; Tretinoin | 2012 |
Quantification of PML/RARa transcript after induction predicts outcome in children with acute promyelocytic leukemia.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Multivariate Analysis; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Real-Time Polymerase Chain Reaction; Remission Induction; Transcription, Genetic; Treatment Outcome; Tretinoin | 2012 |
Mitochondrial myopathy caused by arsenic trioxide therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA Mutational Analysis; Female; Humans; Leukemia, Promyelocytic, Acute; Mitochondria, Muscle; Mitochondrial Myopathies; Oxides; Tretinoin | 2012 |
Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Staging; Oxides; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Treatment Outcome; Tretinoin; Young Adult | 2012 |
[Expression of homeobox A9 in myeloid leukemia cell line HL-60 and effect of drugs on its expression].
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; HL-60 Cells; Homeodomain Proteins; Humans; Leukemia, Myeloid; Oxides; RNA, Messenger; Tretinoin | 2012 |
Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; SEER Program; Time Factors; Tretinoin; United States | 2012 |
Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Mercaptopurine; Middle Aged; Oxides; Retrospective Studies; Tretinoin | 2012 |
ATRA plus arsenic gets another "A" in APL.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2012 |
Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
Topics: Antigens, CD34; Apoptosis; Aquaporins; Arsenic Trioxide; Arsenicals; Biological Transport; Biomarkers, Tumor; CD11b Antigen; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Lewis X Antigen; Oxides; Tretinoin; Up-Regulation | 2012 |
[microRNAs expression profile in acute promyelocytic leukemia cell differentiation induced by all-trans retinoic acid and arsenic trioxide].
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides; RNA, Messenger; Tretinoin; Tumor Cells, Cultured | 2012 |
High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Tretinoin | 2013 |
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Germany; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocyte Count; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Oxides; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk; Thioguanine; Treatment Outcome; Tretinoin | 2013 |
Prognostic significance of CD44v6/v7 in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Female; Humans; Hyaluronan Receptors; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin; Tumor Cells, Cultured; Young Adult | 2012 |
Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Treatment Outcome; Tretinoin; Young Adult | 2012 |
[Effects of cucurmosin combined with common chemotherapeutics on proliferation and apoptosis of NB4 cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Plant Proteins; Tretinoin | 2012 |
All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; STAT5 Transcription Factor; Tretinoin | 2013 |
A case report of acute myeloid leukemia after liver transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Cytarabine; Daunorubicin; Hepatitis B; Humans; Leukemia, Myeloid, Acute; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mitoxantrone; Oxides; Tretinoin | 2013 |
Role of arsenic trioxide in acute promyelocytic leukemia.
Topics: Aminoglycosides; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Randomized Controlled Trials as Topic; Tretinoin | 2013 |
Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.
Topics: Animals; Antineoplastic Agents; Arsenic; Cell Differentiation; Cell Line; Cell Transformation, Neoplastic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Mice; Nuclear Proteins; Promyelocytic Leukemia Protein; Proteolysis; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Transcriptional Activation; Tretinoin; Tumor Suppressor Proteins | 2013 |
Mees lines and Beau lines.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Nail Diseases; Oxides; Remission Induction; Tretinoin | 2013 |
Complete remission of acute promyelocytic leukemia in a very elderly patient after treatment with low dose arsenic trioxide and sequential retinoic acid: a case report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Tretinoin | 2014 |
Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia.
Topics: Antigen Presentation; Arsenic Trioxide; Arsenicals; Cysteine Endopeptidases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Immunologic Factors; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Promoter Regions, Genetic; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Protein Binding; Protein Subunits; Proto-Oncogene Proteins; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Trans-Activators; Transcription Factors; Transcriptional Activation; Transcriptome; Tretinoin; Tumor Escape; Tumor Suppressor Proteins | 2014 |
BCR/ABL fusion gene detected in acute promyelocytic leukemia: a case study of clinical and laboratory results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Piperazines; Pyrimidines; Translocation, Genetic; Treatment Outcome; Tretinoin | 2014 |
Acute promyelocytic leukemia with Flt3-TKD and WT1 mutations relapsing in a testicle and followed by systemic relapse.
Topics: Adult; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Salvage Therapy; Sarcoma, Myeloid; Testicular Neoplasms; Testis; Tretinoin; WT1 Proteins | 2013 |
Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Combined Modality Therapy; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Retrospective Studies; Salvage Therapy; Tetrahydronaphthalenes; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Tretinoin; Young Adult | 2013 |
Targeting agents alone to cure acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2013 |
A single course of all-trans retinoic acid plus arsenic trioxide reached a long-term survival in a patient with newly diagnosed acute promyelocytic leukemia: a suggestion for reduction of treatment courses?
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Treatment Outcome; Tretinoin | 2013 |
3Omics: a web-based systems biology tool for analysis, integration and visualization of human transcriptomic, proteomic and metabolomic data.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Gene Expression Profiling; Humans; Internet; Leukemia, Promyelocytic, Acute; Metabolomics; Oxides; Proteomics; Statistics as Topic; Systems Biology; Tretinoin; Urinalysis | 2013 |
Retinoic acid plus arsenic trioxide, the ultimate panacea for acute promyelocytic leukemia?
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2013 |
Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.
Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Oxides; Prognosis; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tandem Repeat Sequences; Tretinoin; Young Adult | 2013 |
Overcoming treatment resistance in acute promyelocytic leukemia and beyond.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Tretinoin | 2013 |
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Expression of PML-RARα is up-regulated during ATRA and arsenics combined induction without influence on long-term prognosis of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Prognosis; Tretinoin; Up-Regulation; Young Adult | 2013 |
Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Consolidation Chemotherapy; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Neoplasm, Residual; Oxides; Prognosis; Treatment Outcome; Tretinoin | 2013 |
Arsenic trioxide combination improves survival in APL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Remission Induction; Survival Rate; Tretinoin | 2013 |
Treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2013 |
Treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2013 |
The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma.
Topics: Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Codon; Extracellular Signal-Regulated MAP Kinases; Genes, p53; Glioblastoma; Humans; Molecular Sequence Data; Mutation; Neoplastic Stem Cells; Oxides; Tretinoin | 2014 |
Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
Topics: Animals; Arsenic Trioxide; Arsenicals; Computational Biology; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Mice; Microarray Analysis; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proteolysis; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transcription Factors; Tretinoin; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2014 |
Tetra-arsenic tetra-sulfide (As4S 4) promotes apoptosis in retinoid acid -resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.
Topics: Apoptosis; Arsenicals; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Histone Chaperones; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; RNA, Messenger; Sulfides; Transcription Factors; Tretinoin | 2014 |
Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2014 |
Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Survival Analysis; Tretinoin | 2014 |
PML nuclear bodies mediate the therapeutic response of APL cells.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Tretinoin | 2014 |
The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Epigenesis, Genetic; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoid X Receptor alpha; Signal Transduction; Tretinoin | 2014 |
The effect to IL-3Ralpha, downstream PI3k/Akt signaling of all-trans retinoic acid and arsenic trioxide in NB4 cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm; Humans; Interleukin-13 Receptor alpha1 Subunit; Leukemia, Myeloid; Neoplasm Proteins; Oncogene Protein v-akt; Oxides; Phosphatidylinositol 3-Kinases; RNA, Messenger; Signal Transduction; Tretinoin | 2014 |
Guest editorial: acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disseminated Intravascular Coagulation; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2014 |
Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; CD11b Antigen; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Pyrimidines; Tretinoin; Up-Regulation | 2014 |
Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Fetus; Humans; Infant, Newborn; Leukemia, Promyelocytic, Acute; Oxides; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Tretinoin; Young Adult | 2014 |
Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Survival; Drug Synergism; Glutathione; Heme Oxygenase-1; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; NF-E2-Related Factor 2; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin; Tumor Cells, Cultured | 2014 |
All-trans retinoic acid and arsenic trioxide induce apoptosis and modulate intracellular concentrations of calcium in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Carcinoma, Hepatocellular; Cell Proliferation; Hep G2 Cells; Humans; Liver Neoplasms; Oxides; Tretinoin | 2014 |
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Tretinoin; Young Adult | 2015 |
ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin; Young Adult | 2014 |
A prospective, observational study of added medium-dose cytosine arabinoside versus As2O3 for elderly patients with acute promyelocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Polymerase Chain Reaction; Prospective Studies; Survival Rate; Tretinoin | 2014 |
Acute promyelocytic leukaemia with a PML-RARA insertional translocation and a chromosome 21 abnormality in XYY syndrome: case report.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromosomes, Human, Pair 21; Humans; In Situ Hybridization, Fluorescence; Karyotype; Leukemia, Promyelocytic, Acute; Male; Mutagenesis, Insertional; Oncogene Proteins, Fusion; Oxides; Sex Chromosome Disorders; Translocation, Genetic; Treatment Outcome; Tretinoin; XYY Karyotype | 2014 |
Resistance to therapy in acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Mutation; Oncogene Proteins, Fusion; Oxides; Recurrence; Tretinoin | 2014 |
Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Cells, Cultured; Chlorocebus aethiops; COS Cells; Gene Expression Profiling; Humans; Leukemia, Promyelocytic, Acute; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Nude; Mice, Transgenic; Oncogene Proteins, Fusion; Oxides; Promoter Regions, Genetic; Protein Binding; Retinoid X Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sumoylation; Transcriptional Activation; Tretinoin | 2014 |
Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Canada; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Leukemia, Promyelocytic, Acute; Male; Markov Chains; Middle Aged; Monte Carlo Method; Oxides; Quality-Adjusted Life Years; Recurrence; Treatment Failure; Treatment Outcome; Tretinoin | 2015 |
Effects of arsenic compounds on growth, cell-cycle distribution and apoptosis of tretinoin-resistant human promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Caspase 3; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Tretinoin; Tumor Cells, Cultured | 2014 |
How health-related quality-of-life outcomes in patients with acute promyelocytic leukemia can help physicians in decision making.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quality of Life; Tretinoin | 2015 |
Reply to M. Koehler et al.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quality of Life; Tretinoin | 2015 |
Outpatient oral treatment for acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Tretinoin | 2015 |
Outpatient oral treatment for acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Tretinoin | 2015 |
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Mutant Proteins; Mutation; Nuclear Proteins; Nucleophosmin; Oncogene Proteins; Oxides; Tretinoin; Tumor Cells, Cultured; U937 Cells; Xenograft Model Antitumor Assays | 2015 |
Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells.
Topics: Aged; Aged, 80 and over; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Myeloid, Acute; Mutant Proteins; Mutation; Nuclear Proteins; Nucleophosmin; Oxides; Proteolysis; Tretinoin; Tumor Cells, Cultured | 2015 |
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Prospective Studies; Recurrence; Transcription Factors; Tretinoin; Tumor Suppressor Proteins; Young Adult | 2015 |
[Antileukemic].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Humans; Leukemia; Oxides; Remission Induction; Tetrahydronaphthalenes; Tretinoin | 2015 |
ATRA and As₂O₃ regulate differentiation of human hematopoietic stem cells into granulocyte progenitor via alteration of HoxB8 expression.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Survival; Cells, Cultured; Female; Fetal Blood; Gene Expression Regulation; Granulocyte Precursor Cells; Hematopoietic Stem Cells; Homeodomain Proteins; Humans; Infant, Newborn; Oxides; Pregnancy; RNA, Messenger; Tretinoin | 2015 |
Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Topics: Animals; Arsenic Trioxide; Arsenicals; Camptothecin; Cell Differentiation; Cell Movement; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Promyelocytic, Acute; Mice; Mutation; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Polyethylene Glycols; Tretinoin | 2015 |
ATRA and ATO team up against NPM1.
Topics: Animals; Apoptosis; Arsenicals; Humans; Leukemia, Myeloid, Acute; Nuclear Proteins; Nucleophosmin; Oxides; Proteolysis; Tretinoin | 2015 |
[The clinical efficacy of all-trans retinoic acid plus arsenic trioxide in 177 newly diagnosed acute promyelocytic leukemia patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Tretinoin | 2015 |
The Use of Chemical-Chemical Interaction and Chemical Structure to Identify New Candidate Chemicals Related to Lung Cancer.
Topics: Animals; Antineoplastic Agents; Arsenicals; Berberine; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Colchicine; Daunorubicin; Digoxin; Drug Discovery; Humans; Lung; Lung Neoplasms; Ouabain; Prednisone; Small Cell Lung Carcinoma; Tretinoin | 2015 |
Lessons taught by acute promyelocytic leukemia cure.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Tretinoin; Tumor Suppressor Protein p53 | 2015 |
Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2015 |
Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Disease-Free Survival; DNA Mutational Analysis; Epigenesis, Genetic; Female; Genes, Modifier; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Nucleophosmin; Oxides; Prognosis; Treatment Outcome; Tretinoin; Young Adult | 2015 |
Epigenetic Gene Mutations Impact on Outcome in Acute Myeloid Leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2015 |
Chemotherapy-free treatment of acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2015 |
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Case-Control Studies; Cost-Benefit Analysis; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Markov Chains; Models, Economic; Oxides; Treatment Outcome; Tretinoin; United States | 2015 |
Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2015 |
Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Cost Savings; Cost-Benefit Analysis; Direct Service Costs; Female; Health Care Costs; Hospitals, University; Humans; Length of Stay; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Oxides; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Tretinoin; Young Adult | 2015 |
Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Quality of Life; Survival Rate; Tretinoin | 2015 |
Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chromosomes, Human, Pair 17; Female; Humans; Isochromosomes; Leukemia, Promyelocytic, Acute; Middle Aged; Oncogene Proteins, Fusion; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2015 |
Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Oxides; Proportional Hazards Models; Treatment Outcome; Tretinoin; Young Adult | 2015 |
pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice.
Topics: Adjuvants, Immunologic; Animals; Arsenic Trioxide; Arsenicals; Disease Models, Animal; DNA; Immunotherapy; Leukemia, Promyelocytic, Acute; Mice; Oxides; Tretinoin | 2015 |
[History of acute promyelocytic leukemia].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2015 |
Genital vasculitis secondary to all-trans-retinoic-acid.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Genitalia; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin; Vasculitis | 2016 |
Tamoxifen enhances the differentiation-inducing and growth-inhibitory effects of all-trans retinoic acid in acute promyelocytic leukemia cells.
Topics: Animals; Anthracyclines; Antineoplastic Agents, Hormonal; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; CD11b Antigen; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Mice; Mice, Inbred BALB C; Middle Aged; Oxides; Tamoxifen; Tretinoin | 2016 |
Microgranular acute promyelocytic leukemia presenting with leukopenia and an unusual immunophenotype.
Topics: Arsenic Trioxide; Arsenicals; Bone Marrow; Disseminated Intravascular Coagulation; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Leukopenia; Male; Oxides; Treatment Outcome; Tretinoin; Young Adult | 2017 |
Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Blood Coagulation; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Platelet Count; Prothrombin Time; Retrospective Studies; Tretinoin; Young Adult | 2016 |
Arsenic trioxide augments all-trans retinoic acid-induced differentiation of HL-60 cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; HL-60 Cells; Humans; Oxides; Tretinoin | 2016 |
The Effects of Arsenic Trioxide in Combination with Retinoic Acids on Cutaneous T-Cell Lymphoma Cell Lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Lymphoma, T-Cell, Cutaneous; Oxides; Tretinoin | 2016 |
Targeted Therapy Alone for Acute Promyelocytic Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Follow-Up Studies; Humans; Intention to Treat Analysis; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Tretinoin | 2016 |
PHA-Induced Peripheral Blood Cytogenetics and Molecular Analysis: a Valid Diagnostic and Follow-up Modality for Acute Promyelocytic Leukemia Patients Treated with ATRA and/or Arsenic Tri-oxide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blood Cells; Child; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytogenetic Analysis; Female; Follow-Up Studies; Gene Rearrangement; Humans; In Situ Hybridization, Fluorescence; India; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oncogene Proteins, Fusion; Oxides; Phytohemagglutinins; Prognosis; Translocation, Genetic; Tretinoin | 2016 |
Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Polysaccharides; Tretinoin; Xenograft Model Antitumor Assays | 2016 |
Successful treatment of acute promyelocytic leukemia with arsenic trioxide and all-trans retinoic acid in a double lung and kidney transplanted patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Humans; Immunocompromised Host; Kidney Transplantation; Leukemia, Promyelocytic, Acute; Lung Transplantation; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Postoperative Complications; Skin Neoplasms; Tretinoin | 2016 |
Induction treatments for acute promyelocytic leukemia: a network meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Network Meta-Analysis; Oxides; Randomized Controlled Trials as Topic; Tretinoin; Young Adult | 2016 |
Ligand Activity of Group 15 Compounds Possessing Triphenyl Substituent for the RXR and PPARγ Nuclear Receptors.
Topics: Alitretinoin; Arsenicals; Cell Line, Tumor; DNA; Genes, Reporter; Humans; Ligands; Luciferases, Renilla; Organometallic Compounds; Organophosphorus Compounds; PPAR gamma; Retinoid X Receptors; Rosiglitazone; Terphenyl Compounds; Thiazolidinediones; Transcription, Genetic; Tretinoin | 2016 |
Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?
Topics: Acute Disease; Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Oxides; Pericarditis; Remission Induction; Tretinoin | 2017 |
First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2017 |
[Very Severe Differentiation Syndrome in Low Risk Acute Promyelocytic Leukemia - A Peril of Differentiating Therapy].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Diagnosis, Differential; Dyspnea; Female; Fever; Humans; Hypotension; Leukemia, Promyelocytic, Acute; Leukocytosis; Lung Diseases; Oxides; Risk Factors; Severity of Illness Index; Syndrome; Treatment Outcome; Tretinoin | 2017 |
RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspases; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Cyclic AMP; Flow Cytometry; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Ligands; Naphthalenes; Nitro Compounds; Oncogene Proteins, Fusion; Oxides; Protein Binding; Proteolysis; Retinoid X Receptor alpha; Styrenes; Tretinoin | 2017 |
Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Leukemia, Promyelocytic, Acute; Male; Mutation, Missense; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2017 |
Poisoning the Devil.
Topics: Arsenic Trioxide; Arsenicals; China; France; History, 20th Century; History, 21st Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2017 |
Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Case-Control Studies; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Galectin 3; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Analysis; Translocation, Genetic; Treatment Outcome; Tretinoin; Young Adult | 2017 |
Bruising and abnormal leucocytes on a blood film--a haematological emergency.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Contusions; Gingival Hemorrhage; Humans; Lethargy; Leukemia, Promyelocytic, Acute; Leukocytes; Male; Oxides; Tretinoin; Young Adult | 2017 |
Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1β.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; CD11c Antigen; Cell Line, Tumor; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Imidazoles; Interleukin-1beta; JNK Mitogen-Activated Protein Kinases; Leukemia, Promyelocytic, Acute; NF-kappa B; Oxides; p38 Mitogen-Activated Protein Kinases; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thromboplastin; Time Factors; Tretinoin; Tumor Necrosis Factor-alpha; U937 Cells | 2017 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
All-Trans Retinoic Acid Ameliorates Arsenic-Induced Oxidative Stress and Apoptosis in the Rat Uterus by Modulating MAPK Signaling Proteins.
Topics: Animals; Apoptosis; Arsenic; Female; MAP Kinase Signaling System; Oxidative Stress; Rats; Rats, Sprague-Dawley; Tretinoin; Uterus | 2017 |
[Efficacy of Idarubicin-Based Stratified Therapy for Acute Promyelocytic Leukemia].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2017 |
All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Female; Humans; Interferon Regulatory Factors; Leukemia, Promyelocytic, Acute; Male; Monocytes; Neoplasm Proteins; Oxides; Tretinoin | 2017 |
[Role of Microparticles Derived from Acute Promyelocytic Leukemia Cells in Coagulopathy].
Topics: Arsenicals; Blood Coagulation Disorders; Cell-Derived Microparticles; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thromboplastin; Tretinoin | 2017 |
HOXA9 is critical in the proliferation, differentiation, and malignancy of leukaemia cells both in vitro and in vivo.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Down-Regulation; HL-60 Cells; Homeodomain Proteins; Humans; Leukemia; Male; Mice; Mice, Nude; MicroRNAs; Oxides; RNA Interference; RNA, Messenger; Transplantation, Heterologous; Tretinoin | 2017 |
Distinct TP73-DAPK2-ATG5 pathway involvement in ATO-mediated cell death versus ATRA-mediated autophagy responses in APL.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Autophagy-Related Protein 12; Autophagy-Related Protein 5; Cell Line, Tumor; Cell Nucleus; Death-Associated Protein Kinases; Gene Knockdown Techniques; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oxides; Promoter Regions, Genetic; Protein Binding; Protein Isoforms; Protein Stability; Signal Transduction; Transcription, Genetic; Tretinoin; Tumor Protein p73 | 2017 |
Acute promyelocytic leukemia and chronic lymphocytic leukemia diagnosed concurrently.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Bone Marrow; Diabetes Mellitus, Type 2; Humans; Idarubicin; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Multiple Primary; Remission Induction; Tretinoin | 2018 |
[Comparison of Curative Effect between Fu Fang Huang Dai Pian and Arsenic Trioxide in Treatment of 45 Patients with Acute Promyelocytic Leukaemia].
Topics: Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin | 2017 |
[Analysis of Early-Death and Factors Affecting Prognosis of Patients with Acute Promyelocytic Leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Retrospective Studies; Tretinoin | 2018 |
[Acute Promyelocytic Leukemia - A Rare, Life-Threatening Disease with High Healing Chance].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Rare Diseases; Tretinoin | 2018 |
Case report: Purulent transformation of granulocytic sarcoma: An unusual pattern of differentiation in acute promyelocytic leukemia.
Topics: Abdomen; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Sarcoma, Myeloid; Suppuration; Tretinoin | 2018 |
Influence of acute promyelocytic leukemia therapeutic drugs on nuclear pore complex density and integrity.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line; Cell Nucleus; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Mitosis; Nuclear Envelope; Nuclear Pore; Oxides; Permeability; Tretinoin | 2018 |
Cutaneous herald: leukaemia cutis as presenting manifestation of relapse in acute promyelocytic leukaemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biopsy; Consolidation Chemotherapy; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Oxides; Skin; Tretinoin | 2018 |
Oral arsenic and all-
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Arsenic; Cohort Studies; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Treatment Outcome; Tretinoin; Young Adult | 2018 |
Self-Assembled Nanocomplex for Co-Delivery of Arsenic-Retinoic Acid Prodrug into Acute Promyelocytic Leukemia Cells.
Topics: Antineoplastic Agents; Arsenic; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prodrugs; Tretinoin | 2018 |
Towards home-based treatment for acute promyelocytic leukaemia, with caution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2018 |
[Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Retrospective Studies; Tretinoin | 2018 |
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2018 |
Salinomycin induces apoptosis and differentiation in human acute promyelocytic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imides; Leukemia, Promyelocytic, Acute; Oxides; Pyrans; Quinolines; Tretinoin; Wnt Signaling Pathway | 2018 |
Arsenic and old
Topics: Animals; Arsenic; fms-Like Tyrosine Kinase 3; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mice; Tretinoin | 2019 |
Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost-effective?
Topics: Arsenic Trioxide; Arsenicals; China; Cost-Benefit Analysis; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2020 |
[Efficacy of Arsenic Trioxide Combined with ATRA and Chemotherapy for Relapsed Acute Promyelocytic Leukemia Patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2020 |
Arsenic represses airway epithelial mucin expression by affecting retinoic acid signaling pathway.
Topics: Arsenic; Arsenites; Cell Line; Cell Survival; ErbB Receptors; Gene Expression; Gene Expression Regulation; Humans; Mucin 5AC; Mucin-5B; Mucins; Respiratory Mucosa; Signal Transduction; Sodium Compounds; Tretinoin | 2020 |
Severe Wernicke encephalopathy and acute pancreatitis due to all-trans-retinoic acid and arsenic trioxide during treatment of acute promyelocytic leukaemia: a case report.
Topics: Acute Disease; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Pancreatitis; Tretinoin; Wernicke Encephalopathy | 2020 |
Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Herpes Zoster; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2021 |
Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia.
Topics: Arsenic Trioxide; Arsenicals; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Transplantation, Autologous; Tretinoin | 2021 |
Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2021 |
A call to action for the treatment of acute promyelocytic leukemia in the modern era: It is no longer just about the ATRA and arsenic.
Topics: Arsenic; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2021 |
Arsenic and all-
Topics: Arsenic; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2021 |
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2022 |
Impact of sociodemographic factors on early mortality in acute promyelocytic leukemia in the United States: A time-trend analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Sociodemographic Factors; Treatment Outcome; Tretinoin; United States | 2022 |
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
Topics: Animals; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Leukemia, Promyelocytic, Acute; Mice; Oxides; Tretinoin | 2022 |
The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2022 |
Bone marrow necrosis as complication of treatment with all-trans retinoic acid and arsenic trioxide: case report and implications for treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Humans; Leukemia, Promyelocytic, Acute; Necrosis; Tretinoin | 2022 |
[Refractory acute promyelocytic leukemia with a complex karyotype].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Female; Hematopoietic Stem Cell Transplantation; Humans; Karyotype; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Transplantation, Autologous; Treatment Outcome; Tretinoin | 2021 |
Gemtuzumab Ozogamicin Followed by Unrelated Cord Blood Transplantation With Reduced-intensity Conditioning for a Child With Refractory Acute Promyelocytic Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cord Blood Stem Cell Transplantation; Female; Gemtuzumab; Humans; Infant; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2022 |
Venetoclax for arsenic-resistant acute promyelocytic leukaemia.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Sulfonamides; Tretinoin | 2022 |
Subcellular Partitioning of Arsenic Trioxide Revealed by Label-Free Imaging.
Topics: Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Protein Aggregates; Sulfur; Tretinoin | 2022 |
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2022 |
Tetra-arsenic tetra-sulfide enhances NK-92MI mediated cellular immunotherapy in all-trans retinoic acid-resistant acute promyelocytic leukemia.
Topics: Animals; Arsenic; Arsenicals; Immunotherapy; Leukemia, Promyelocytic, Acute; Mice; Oxides; Sulfides; Tretinoin; Tumor Microenvironment | 2022 |
Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA, Mitochondrial; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2023 |
Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-centre study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2023 |
Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2023 |
Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Transcription Factors; Tretinoin; Ubiquitination | 2023 |
Transglutaminase 2 associated with PI3K and PTEN in a membrane-bound signalosome platform blunts cell death.
Topics: Arsenic Trioxide; Arsenicals; Cell Death; Humans; Integrins; Leukemia, Promyelocytic, Acute; Mechanistic Target of Rapamycin Complex 2; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Protein Glutamine gamma Glutamyltransferase 2; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; TOR Serine-Threonine Kinases; Tretinoin | 2023 |
Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Repressor Proteins; Retinoic Acid Receptor alpha; Tretinoin | 2023 |
Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2023 |
ATO Increases ROS Production and Apoptosis of Cells by Enhancing Calpain-Mediated Degradation of the Cancer Survival Protein TG2.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Calpain; Humans; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Oxides; Protein Glutamine gamma Glutamyltransferase 2; Reactive Oxygen Species; Tretinoin | 2023 |
Utility of end of induction bone marrow biopsy and survival outcomes in acute promyelocytic leukemia treated with fixed-dose induction regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin | 2023 |
Additional cytogenetic abnormalities in patients with newly diagnosed acute promyelocytic leukemia predict inferior event-free survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Chromosome Aberrations; Humans; Leukemia, Promyelocytic, Acute; Oxides; Progression-Free Survival; Retrospective Studies; Treatment Outcome; Tretinoin | 2023 |